e424b5
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed |
|
|
Proposed |
|
|
|
|
|
|
|
|
Amount |
|
|
maximum |
|
|
maximum |
|
|
Amount of |
|
|
Title of each class of |
|
|
to be |
|
|
offering |
|
|
aggregate |
|
|
registration |
|
|
securities to be registered |
|
|
registered (1) |
|
|
price per share |
|
|
offering price |
|
|
fee (2) |
|
|
Common Stock, par value
$0.001 per share |
|
|
3,680,000 |
|
|
$21.645(2) |
|
|
$79,653,600 |
|
|
$5,679.30(3) |
|
|
|
|
|
(1) |
|
Includes 480,000 shares of common stock that may be purchased by the underwriter pursuant to
its option to purchase additional shares of common stock to cover overallotments, if any. |
|
(2) |
|
Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c)
under the Securities Act of 1933, as amended (the Act) and based on the average of the high and
low prices of NxStage Medical Inc.s common stock as reported on The Nasdaq Global Market on
November 16, 2010. |
|
(3) |
|
Calculated in accordance with Rule 457(r) under the Act. |
Filed
Pursuant to Rule 424(b)(5)
Registration Statement
No. 333-170654
Prospectus Supplement (To Prospectus dated November 17,
2010)
3,200,000 Shares
NxStage Medical, Inc.
Common Stock
We are offering to sell 3,200,000 shares of our common
stock, par value $0.001.
Our common stock is listed on The NASDAQ Global Market under the
symbol NXTM. On November 17, 2010 the last
reported sales price per share of our common stock on The NASDAQ
Global Market was $21.38.
Investing in our common stock involves a high degree of risk.
You should read carefully this prospectus supplement, the
documents incorporated by reference in this prospectus
supplement and the accompanying base prospectus before you
invest. Please see Risk Factors on
page S-3
for more information.
The underwriter has agreed to purchase from us the common stock
being offered by us pursuant to this prospectus supplement at a
price of $20.04 per share, which will result in $64,128,000 of
proceeds to us (before expenses). We have granted the
underwriter the right to purchase up to an additional
480,000 shares of our common stock at a price of $20.04 per
share to cover over-allotments, if any.
The underwriter may offer our common stock from time to time in
one or more transactions in the
over-the-counter
market or through negotiated transactions at market prices or at
negotiated prices.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this
prospectus supplement. Any representation to the contrary is a
criminal offense.
Canaccord Genuity
The date of this prospectus supplement is November 17,
2010
TABLE OF
CONTENTS
Prospectus
Supplement
|
|
|
|
|
|
|
|
S-1
|
|
|
|
|
S-2
|
|
|
|
|
S-3
|
|
|
|
|
S-4
|
|
|
|
|
S-5
|
|
|
|
|
S-6
|
|
|
|
|
S-7
|
|
|
|
|
S-8
|
|
|
|
|
S-9
|
|
|
|
|
S-10
|
|
|
|
|
S-12
|
|
|
|
|
S-15
|
|
|
|
|
S-15
|
|
Prospectus
|
|
|
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
18
|
|
|
|
|
19
|
|
|
|
|
20
|
|
|
|
|
20
|
|
|
|
|
20
|
|
S-i
ABOUT
THIS PROSPECTUS SUPPLEMENT
This document consists of two parts. The first part is this
prospectus supplement, which describes the specific terms of
this offering and adds to and updates information contained in
the accompanying base prospectus and the documents incorporated
by reference into the prospectus supplement and the accompanying
base prospectus. The second part is the accompanying base
prospectus, which gives more general information, some of which
may not apply to this offering, about us and the common stock
offered hereby. To the extent the information contained in this
prospectus supplement differs or varies from the information
contained in the accompanying base prospectus or any document
incorporated by reference, the information in this prospectus
supplement shall control and you should rely on the information
in this prospectus supplement. You should read both this
prospectus supplement and the accompanying base prospectus,
together with the additional information described below under
the headings Where You Can Find More Information and
Incorporation of Certain Information by Reference.
We have not authorized anyone to provide any information other
than that contained or incorporated by reference in this
prospectus supplement or in any free writing prospectus prepared
by or on behalf of us or to which we have referred you. We take
no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you.
Neither we nor the underwriter have authorized any dealer,
salesman or other person to give any information or to make any
representation other than those contained or incorporated by
reference in this prospectus supplement and the accompanying
base prospectus. You must not rely upon any information or
representation not contained or incorporated by reference in
this prospectus supplement or any accompanying base prospectus.
This prospectus supplement and the accompanying base prospectus
do not constitute an offer to sell or the solicitation of an
offer to buy any securities other than the registered securities
to which they relate, nor do this prospectus supplement and the
accompanying base prospectus constitute an offer to sell or the
solicitation of an offer to buy securities in any jurisdiction
to any person to whom it is unlawful to make such offer or
solicitation in such jurisdiction. You should not assume that
the information contained in this prospectus supplement, the
accompanying base prospectus or the documents incorporated by
reference is accurate on any date other than their respective
dates. Our business, financial condition, results of operations
and prospects may have changed since those dates.
Unless the context otherwise requires or as otherwise expressly
stated, references in this prospectus supplement to the
Company, NxStage, we,
us and our and similar terms refer to
NxStage Medical, Inc. and our subsidiaries on a consolidated
basis.
S-ii
PROSPECTUS
SUPPLEMENT SUMMARY
This prospectus supplement summary does not contain all the
information you should consider before investing in our common
stock. Please read the entire prospectus supplement and the
accompanying base prospectus, including the financial statements
and other information incorporated herein by reference.
Our
Company
We are a medical device company that develops, manufactures and
markets innovative products for the treatment of kidney failure,
fluid overload and related blood treatments and procedures. Our
primary product, the NxStage System One, or System One, was
designed to satisfy an unmet clinical need for a system that can
deliver the therapeutic flexibility and clinical benefits
associated with traditional dialysis machines in a smaller,
portable, easy-to-use form that can be used by healthcare
professionals and trained lay users alike in a variety of
settings, including patient homes, as well as more traditional
care settings such as hospitals and dialysis clinics. Given its
design, the System One is particularly well-suited for home
hemodialysis and a range of dialysis therapies including more
frequent, or daily, dialysis, which clinical
literature suggests provides patients better clinical outcomes
and improved quality of life.
The System One is cleared by the United States Food and Drug
Administration, or FDA, for home hemodialysis as well as
hospital and clinic-based dialysis. We also sell needles and
blood tubing sets primarily to dialysis clinics for the
treatment of end-stage renal disease, or ESRD, which we refer to
as the in-center market. We believe our largest future product
market opportunity is for our System One used in the home
hemodialysis market, or home market, for the treatment of ESRD.
We report the results of our operations in two segments: System
One and In-Center. We distribute our products in three markets:
home, critical care and in-center. In the System One segment we
derive our revenues from the sale and rental of equipment and
the sale of disposable products in the home and critical care
markets. We define the home market as the market devoted to the
treatment of ESRD patients in the home and the critical care
market as the market devoted to the treatment of hospital-based
patients with acute kidney failure or fluid overload. In the
In-Center segment, we derive our revenues from the sale of
needles and blood tubing sets primarily used for in-center
dialysis treatments.
Within the System One segment, we offer a similar technology
platform of the System One for the home and critical care
markets with different features. The FDA has cleared the System
One for hemodialysis, hemofiltration and ultrafiltration. We
offer primarily needles and blood tubing sets in the In-Center
segment. Our products are predominantly used by our customers to
treat patients suffering from ESRD or acute kidney failure. We
have marketing and sales efforts dedicated to each market,
although nearly all sales in the In-Center segment are made
through distributors.
We were incorporated in Delaware in 1998 under the name QB
Medical, Inc, and later changed our name to NxStage Medical,
Inc. Financial results in each of our two reportable segments,
including information about revenues from customers, measures of
profit and loss, and total assets are discussed in our annual
consolidated financial statements that are incorporated by
reference herein.
The address of our principal executive office is 439 South Union
Street, Fifth Floor, Lawrence, Massachusetts 01843 and our
telephone number is
(978) 687-4700.
Our internet website is www.nxstage.com. We make our electronic
filings with the Securities Exchange Commission (the
SEC), including our annual reports on
Form 10-K,
quarterly reports on
Form 10-Q,
current reports on
Form 8-K
and amendments to these reports available on our website free of
charge as soon as practicable after we file or furnish them with
the SEC. Information on our website is not a part of, or
incorporated by reference into, this prospectus supplement.
S-1
THE
OFFERING
|
|
|
Common stock offered |
|
3,200,000 shares |
|
Common stock to be outstanding after this offering |
|
52,305,809 shares (1) |
|
Over-allotment option |
|
We have granted the underwriter an option to purchase up to
480,000 shares of our common stock at a price of $20.04 per
share to cover over-allotments, if any. This option is
exercisable, in whole or in part, for a period of 30 days
from the date of this prospectus supplement. |
|
Use of proceeds |
|
We expect to receive net proceeds of approximately
$63.7 million (or approximately $73.3 million if the
underwriters over-allotment option is exercised in full),
after deducting estimated offering expenses payable by us. We
expect to use the net proceeds of the offering for working
capital and general corporate purposes. |
|
Nasdaq Global Market symbol for common stock |
|
Our common stock is listed on The Nasdaq Global Market under the
symbol NXTM. |
|
Risk Factors |
|
See Risk Factors and the other information contained
in this prospectus supplement and to which we refer you for a
discussion of factors you should consider carefully before
deciding to invest in our securities. |
|
Transfer Agent and Registrar |
|
Computershare |
Unless we indicate otherwise, the information in this prospectus
supplement assumes that the underwriter will not exercise its
over-allotment option.
|
|
(1) |
The number of shares of our common stock to be outstanding after
this offering is based on 49,105,809 shares outstanding as
of September 30, 2010 and, unless otherwise indicated,
excludes:
|
|
|
|
|
|
7,186,556 shares of common stock issuable upon the exercise
of outstanding options, of which 4,338,074 shares were
exercisable as of September 30, 2010, with a weighted
average exercise price of $7.60 per share;
|
|
|
|
818,444 shares reserved for issuance as restricted stock
pursuant to outstanding equity compensation awards, nearly all
of which are issuable upon the achievement of certain
performance criteria;
|
|
|
|
787,698 shares of common stock reserved for future issuance
under our equity incentive plans; and
|
|
|
|
7,133,329 shares of common stock issuable upon the exercise
of outstanding warrants of which 5,500,000 shares are issuable
based upon the achievement of certain performance criteria.
|
S-2
RISK
FACTORS
Investing in our securities involves a high degree of risk. You
should carefully consider and evaluate all of the information
contained in this prospectus supplement, the accompanying base
prospectus, and in the documents we incorporate by reference in
this prospectus supplement before you decide to purchase our
securities. In particular, you should carefully consider and
evaluate the risks and uncertainties described in
Part I Item 1A. Risk Factors
of our
Form 10-K
for the year ended December 31, 2009 and in
Part II Item 1A. Risk Factors
of our
Form 10-Q
for the quarterly period ended September 30, 2010, in each
case as updated by the additional risks and uncertainties set
forth in other filings we make with the SEC. Any of the risks
and uncertainties set forth therein could materially and
adversely affect our business, results of operations and
financial condition, which in turn could materially and
adversely affect the trading price or value of our securities.
As a result, you could lose all or part of your investment.
S-3
WHERE YOU
CAN FIND MORE INFORMATION
We are currently subject to the reporting requirements of the
Securities Exchange Act of 1934, as amended (the Exchange
Act) and in accordance therewith file periodic reports,
proxy statements and other information with the Securities and
Exchange Commission. You may read and copy (at prescribed rates)
any such reports, proxy statements and other information at the
SECs Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the operation of the public reference
room. Our SEC filings will also be available to you on the
SECs website at
http://www.sec.gov
and in the Investors section of our website at
http://www.nxstage.com.
Our website and the information contained on that site, or
connected to that site, are not incorporated into and are not a
part of this prospectus supplement.
We have filed with the SEC a registration statement on
Form S-3
with respect to the securities offered hereby. This prospectus
supplement does not contain all the information set forth in the
registration statement, parts of which are omitted in accordance
with the rules and regulations of the SEC. For further
information with respect to us and the securities offered
hereby, reference is made to the registration statement.
S-4
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
We incorporate information into this prospectus supplement by
reference, which means that we disclose important information to
you by referring you to another document filed separately with
the SEC. The information incorporated by reference is deemed to
be part of this prospectus supplement, except to the extent
superseded by information contained in this prospectus
supplement. This prospectus supplement incorporates by reference
the documents set forth below, the file number for each of which
is
000-51567,
that have been previously filed with the SEC:
|
|
|
|
|
our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2009, filed with the
SEC on March 12, 2010;
|
|
|
|
our Proxy Statement for our 2010 Annual Meeting of Stockholders,
filed with the SEC on April 29, 2010;
|
|
|
|
our Quarterly Reports on
Form 10-Q
for the quarterly periods ended March 31, 2010,
June 30, 2010 and September 30, 2010;
|
|
|
|
our Current Reports on
Form 8-K
filed with the SEC on March 5, 2010, June 1, 2010 and
July 23, 2010 (but not including the information under, or
incorporated by reference into, Item 7.01 of the
Form 8-K
filed on July 23, 2010); and
|
|
|
|
the description of our common stock, par value $0.001 per share,
contained in our Registration Statement on
Form 8-A,
filed pursuant to Section 12 of the Exchange Act on
October 7, 2005 (Registration
No. 000-51567),
including any amendments or reports filed to update such
information.
|
In addition, all documents that we file with the SEC pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act
after the date of the initial registration statement of which
this prospectus supplement is a part and all such documents that
we file with the SEC after the date of this prospectus
supplement and before the termination of the offering of our
securities shall be deemed incorporated by reference into this
prospectus supplement and to be a part of this prospectus
supplement from the respective dates of filing such documents.
Unless specifically stated to the contrary, none of the
information that we disclose under Items 2.02 or 7.01 of
any Current Report on
Form 8-K
that we may from time to time furnish to the SEC will be
incorporated by reference into, or otherwise included in, this
prospectus supplement.
Any statement contained in a document incorporated by reference
in this prospectus supplement shall be deemed to be modified or
superseded for purposes of this prospectus supplement to the
extent that a statement contained in this prospectus supplement
or in any other subsequently filed document that also is or is
deemed to be incorporated by reference in this prospectus
supplement modifies or supersedes such statement. Any statement
so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this prospectus
supplement.
You may obtain copies of any of these filings by contacting us
at the address and telephone number indicated below or by
contacting the SEC as described above under the section entitled
Where You Can Find More Information. Documents
incorporated by reference are available from us without charge,
excluding all exhibits unless an exhibit has been specifically
incorporated by reference into this prospectus supplement, by
requesting them in writing or by telephone at:
NxStage
Medical, Inc.
Attention: Corporate Secretary
439 South Union Street, 5th Floor
Lawrence, MA 01843
(978) 687-4700
S-5
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement contains or incorporates by reference
forward-looking statements within the meaning of
Section 27A of the Securities Act and Section 2 1E of
the Exchange Act. Forward-looking statements may include the
words may, will, estimate,
intend, continue, believe,
expect, plan or anticipate
and other similar words. Our forward-looking
statements include, but are not limited to, statements
regarding:
|
|
|
|
|
our business, operations and financial condition;
|
|
|
|
the market adoption of our products in the United States and
internationally;
|
|
|
|
the growth of the home, critical care and in-center dialysis
markets in general and the home hemodialysis market in
particular;
|
|
|
|
the development and commercialization of our products;
|
|
|
|
changes in the historical purchasing patterns and preferences of
our major customers, including DaVita Inc.;
|
|
|
|
the adequacy of our funding;
|
|
|
|
our ability to sustain positive cash flows;
|
|
|
|
our need for and our ability to obtain additional funding;
|
|
|
|
whether and when we might achieve improvements to our gross
margins and operating expenses;
|
|
|
|
expectations with respect to our operating expenses and
achieving our business plan;
|
|
|
|
expectations with respect to achieving profitable operations;
|
|
|
|
expectations with respect to achieving improvements in product
reliability;
|
|
|
|
the timing and success of the submission, acceptance and
approval of regulatory filings and the impact of any changes in
the regulatory environment with respect to our products or
business;
|
|
|
|
the scope of patent protection with respect to our products;
|
|
|
|
the timing and success of competitive product offerings;
|
|
|
|
expectations with respect to the clinical findings of our
FREEDOM study;
|
|
|
|
the impact of future changes to reimbursement for chronic
dialysis treatments and the impact current economic conditions
on our business; and
|
|
|
|
assumptions relating to the foregoing.
|
Our future financial condition and results of operations, as
well as any forward-looking statements, are subject to change
and are subject to inherent risks and uncertainties, such as
those disclosed in this prospectus supplement. Important risks
and factors that could cause our actual results to be materially
different from our expectations include the factors that are
disclosed in Part I Item 1A. Risk
Factors of our most recent Annual Report on
Form 10-K
and in Part II Item 1A. Risk
Factors of our Form 10-Q for the quarterly period ended
September 30, 2010, in each case as updated by the additional
risks and uncertainties set forth in other filings we make with
the SEC. You should read these factors and the other cautionary
statements made in this prospectus supplement as being
applicable to all related forward-looking statements wherever
they appear in this prospectus supplement. Each forward-looking
statement contained in this prospectus supplement reflects
managements view only as of the date on which that
forward-looking statement was made. We are not obligated to
update forward-looking statements or publicly release the result
of any revisions to them to reflect events or circumstances
after the date of this prospectus supplement or to reflect the
occurrence of unanticipated events.
S-6
USE OF
PROCEEDS
We expect to receive net proceeds of approximately
$63.7 million after deducting estimated offering expenses
payable by us, assuming no exercise of the underwriters
over-allotment option. If the underwriter exercises in full its
option to purchase 480,000 additional shares, we expect to
receive net proceeds of approximately $73.3 million after
deducting estimated offering expenses payable by us.
We intend to use the net proceeds from this offering for working
capital and general corporate purposes.
S-7
CAPITALIZATION
The following table sets forth our capitalization as of
September 30, 2010:
|
|
|
|
|
on an actual basis; and
|
|
|
|
as adjusted to give effect to the receipt of the proceeds of the
offering less estimated offering expenses.
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2010
|
|
|
|
Actual
|
|
|
As Adjusted
|
|
|
|
(In thousands except share data)
|
|
|
|
(Unaudited)
|
|
|
Cash and cash equivalents
|
|
$
|
21,974
|
|
|
$
|
85,627
|
|
|
|
|
|
|
|
|
|
|
Current Portion of Long Term Debt
|
|
$
|
59
|
|
|
$
|
59
|
|
|
|
|
|
|
|
|
|
|
Long Term debt
|
|
$
|
39,779
|
|
|
$
|
39,779
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Undesignated preferred stock, par value $0.001,
5,000,000 shares authorized, no shares issued and
outstanding as of September 30, 2010, no shares issued and
outstanding as adjusted
|
|
|
|
|
|
|
|
|
Common Stock, par value $0.001, 100,000,000 shares
authorized, 49,310,143 shares issued as of
September 30, 2010, 52,510,143 shares issued as
adjusted
|
|
$
|
49
|
|
|
$
|
52
|
|
Additional paid-in capital
|
|
$
|
381,585
|
|
|
$
|
445,235
|
|
Accumulated deficit
|
|
$
|
(302,133
|
)
|
|
$
|
(302,133
|
)
|
Accumulated other comprehensive income
|
|
$
|
244
|
|
|
$
|
244
|
|
Treasury stock, at cost: 204,334 shares as of
September 30, 2010 and as adjusted
|
|
$
|
(2,232
|
)
|
|
$
|
(2,232
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
$
|
77,513
|
|
|
$
|
141,166
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
117,351
|
|
|
$
|
181,004
|
|
|
|
|
|
|
|
|
|
|
The table assumes that the underwriters option to purchase
additional shares related to this offering is not exercised.
You should read this table together with our financial
statements and notes thereto and other financial and operating
data included elsewhere in this prospectus supplement or in the
accompanying base prospectus or incorporated by reference into
this prospectus supplement or the accompanying base prospectus.
S-8
DILUTION
If you purchase our common stock in this offering, your interest
will be diluted to the extent of the difference between the
offering price per share and the net tangible book value per
share of our common stock after this offering. Our net tangible
book value at September 30, 2010, was $8.7 million, or
$0.18 per share, based on 49,105,809 shares of our common
stock outstanding as of that date. After giving effect to the
sale of 3,200,000 shares of common stock by us at an
assumed public offering price of $20.65 per share, less the
discount to the underwriter and estimated offering expenses, our
net tangible book value as of September 30, 2010, would
have been approximately $72.4 million, or $1.38 per share.
This represents an immediate increase in the net tangible book
value of approximately $1.20 per share to existing stockholders
and an immediate dilution of $19.27 per share to investors in
this offering. The following table illustrates this per share
dilution:
|
|
|
|
|
|
|
|
|
Assumed Public Offering price per share
|
|
|
|
|
|
$
|
20.65
|
|
Net tangible book value per share as of September 30, 2010
|
|
$
|
0.18
|
|
|
|
|
|
Increase in net tangible book value per share after this offering
|
|
$
|
1.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net tangible book value per share after this offering
|
|
|
|
|
|
$
|
1.38
|
|
|
|
|
|
|
|
|
|
|
Dilution per share to new investors
|
|
|
|
|
|
$
|
19.27
|
|
|
|
|
|
|
|
|
|
|
Assuming the exercise in full of the underwriters
overallotment option, our net tangible book value at
September 30, 2010 would have been approximately $1.55 per
share, representing an immediate increase in the net tangible
book value of approximately $1.37 per share to our existing
stockholders and an immediate dilution in net tangible book
value of $19.10 per share to new investors.
The foregoing tables and calculations are based on shares of our
common stock outstanding as of September 30, 2010 and
excludes:
|
|
|
|
|
7,186,556 shares of common stock issuable upon the exercise
of outstanding options, of which 4,338,074 shares were
exercisable as of September 30, 2010, with a weighted
average exercise price of $7.60 per share;
|
|
|
|
818,444 shares reserved for issuance as restricted stock
pursuant to outstanding equity compensation awards, nearly all
of which are issuable upon the achievement of certain
performance criteria;
|
|
|
|
787,698 shares of common stock reserved for future issuance
under our equity incentive plans; and
|
|
|
|
7,133,329 shares of common stock issuable upon the exercise
of outstanding warrants of which 5,500,000 shares are issuable
based upon the achievement of certain performance criteria.
|
To the extent that outstanding warrants and options are
exercised and restricted stock issued in the future, there will
be further dilution to new investors. To the extent all of such
outstanding options and warrants had been exercised and
restricted stock issued as of September 30, 2010, net
tangible book value per share after this offering would have
been $3.18 per share and total dilution per share to new
investors would have been $17.47 per share.
S-9
UNDERWRITING
We intend to offer shares of our common stock through the
underwriter, Canaccord Genuity Inc. We have agreed to sell to
the underwriter, and the underwriter has agreed to purchase from
us, 3,200,000 shares of our common stock at $20.04 per
share.
The underwriter has agreed to purchase all of the shares of our
common stock (other than those covered by the over-allotment
option described below) sold under the underwriting agreement.
The underwriter is offering the shares of our common stock,
when, as and if issued to and accepted by it, subject to
approval of legal matters by its counsel, including the validity
of the common stock and other conditions contained in the
underwriting agreement, such as the receipt by the underwriter
of officers certificates and legal opinions. The
underwriter may offer our common stock from time to time in one
or more transactions in the
over-the-counter
market or through negotiated transactions at market prices or at
negotiated prices. The underwriter reserves the right to
withdraw, cancel or modify offers to the public and to reject
orders in whole or in part.
We have agreed to indemnify the underwriter against certain
liabilities, including liabilities under the Securities Act, and
to contribute to payments that the underwriter may be required
to make in respect of those liabilities.
Commissions
and Discounts
In connection with the sale of the shares of common stock
offered hereby, the underwriter may be deemed to have received
compensation in the form of underwriting discounts representing
the difference between the price paid to us for the shares of
our common stock ($20.04) and the public offering price paid by
investors in the offering.
The expenses of the offering are estimated to be approximately
$475,000. We are responsible for all of our expenses related to
the offering, whether or not it is completed and up to $80,000
of the expenses of the underwriter, including reasonable fees
and expenses of the underwriters legal counsel.
Over-Allotment
Option
We have granted an option to the underwriter to purchase up to
480,000 additional shares of our common stock at $20.04 per
share. The underwriter may exercise this option for 30 days
from the date of this prospectus supplement solely to cover any
over-allotments.
Lock-Up
Agreements
We and our executive officers and directors have entered into
lock-up
agreements with the underwriter. Under these agreements, we and
each of these persons may not, without the prior written
approval of the underwriter, subject to limited exceptions,
offer, sell, assign, transfer, contract to sell, or otherwise
dispose of, or announce the intention to otherwise dispose of,
or enter into any swap or other arrangement that transfers any
economic consequences of ownership of our common stock or
securities convertible into or exercisable or exchangeable for
our common stock. These restrictions will be in effect for a
period of 75 days after the date of this prospectus
supplement with respect to NxStage and 20 days after the
date of this prospectus supplement with respect to our executive
officers and directors. At any time and without public notice,
the underwriter may in its sole discretion release all or some
of the securities from these
lock-up
agreements.
Price
Stabilization and Short Positions
Until distribution of the shares of our common stock is
completed, SEC rules may limit the underwriter from bidding for
and purchasing shares of our common stock. However, the
underwriter may engage in transactions that stabilize the price
of the shares of our common stock, such as bids or purchases to
peg, fix or maintain that price.
If the underwriter creates a short position in our common stock
in connection with this offering (i.e., if it sells more shares
of our common stock than are listed on the cover page of this
prospectus supplement), the
S-10
underwriter may reduce that short position by purchasing shares
of our common stock in the open market. The underwriter may also
elect to reduce any short position by exercising all or part of
the over-allotment option described above. Purchases of shares
of our common stock to stabilize its price or to reduce a short
position may cause the price of shares of our common stock to be
higher than it might be in the absence of such purchases.
The underwriter also may impose a penalty bid, whereby the
underwriter may reclaim selling concessions allowed to other
broker-dealers in respect of the common stock sold in the
offering for their account if the underwriter repurchases the
shares in stabilizing or covering transactions. These activities
may stabilize, maintain or otherwise affect the market price of
the common stock, which may be higher than the price that might
otherwise prevail in the open market. The imposition of a
penalty bid may also affect the price of the shares of our
common stock in that it discourages resales of those shares of
our common stock.
The underwriter has advised us that these transactions may be
effected on The NASDAQ Global Market or otherwise. Neither we
nor the underwriter make any representation or prediction as to
the direction or magnitude of any effect that the transactions
described above may have on the price of shares of our common
stock. In addition, neither we nor the underwriter makes any
representation that the underwriter will engage in these
transactions or that these transactions, once commenced, will
not be discontinued without notice.
Relationship
with NxStage
In the ordinary course of business, the underwriter and its
affiliates may, in the future, engage in investment banking or
other transactions of financial nature with us, including the
provision of certain advisory services to us or financing
transactions for which they may receive customary compensation.
S-11
MATERIAL
U.S. FEDERAL TAX CONSIDERATIONS FOR
NON-U.S.
HOLDERS
The following is a general discussion of the material
U.S. federal income and estate tax consequences of the
ownership and disposition of our common stock by a
non-U.S. holder.
For purposes of this discussion, you are a
non-U.S. holder
if you are a beneficial owner of our common stock, and you are
not, for U.S. federal income tax purposes:
|
|
|
|
|
an individual who is a citizen or resident of the U.S.;
|
|
|
|
a corporation (or other entity treated as a corporation for
U.S. federal income tax purposes) created or organized in
or under the laws of the U.S., or of any state thereof or the
District of Columbia; or
|
|
|
|
an estate whose income is subject to U.S. federal income
taxation regardless of its source; or a trust, in general, if a
U.S. court is able to exercise primary supervision over the
administration of the trust and one or more U.S. persons
have authority to control all substantial decisions of the trust
or if the trust has made a valid election to be treated as a
U.S. person under applicable U.S. Treasury regulations.
|
If you are an individual, you may be treated as a resident of
the U.S. in any calendar year for U.S. federal income
tax purposes, instead of a nonresident, by, among other ways,
being present in the U.S. for at least 31 days in that
calendar year and for an aggregate of at least 183 days
during a three-year period ending in the current calendar year.
For purposes of this calculation, you would count all of the
days present in the current year, one-third of the days present
in the immediately preceding year and one-sixth of the days
present in the second preceding year. Residents of the
U.S. are taxed for U.S. federal income tax purposes as
if they were U.S. citizens.
This discussion does not consider:
|
|
|
|
|
U.S. state, U.S. local or
non-U.S. tax
consequences;
|
|
|
|
all aspects of U.S. federal income and estate taxes or
specific facts and circumstances that may be relevant to a
particular
non-U.S. holders
tax position;
|
|
|
|
the tax consequences for the stockholders, partners or
beneficiaries of a
non-U.S. holder;
|
|
|
|
special tax rules that may apply to particular
non-U.S. holders,
such as financial institutions, insurance companies, tax-exempt
organizations, U.S. expatriates, broker-dealers and traders
in securities; or
|
|
|
|
special tax rules that may apply to a
non-U.S. holder
that holds our common stock as part of a straddle,
hedge, conversion transaction,
synthetic security or other integrated investment.
|
If a partnership, including any entity treated as a partnership
for U.S. federal income tax purposes, is a holder of our
common stock, the tax treatment of a partner in the partnership
will generally depend upon the status of the partner and the
activities of the partnership. If you are a partnership that may
acquire our common stock, or a partner in such a partnership,
you should consult a tax advisor regarding the tax consequences
to you of the partnerships acquisition, ownership and
disposition of our common stock.
The following discussion is based on provisions of the
U.S. Internal Revenue Code of 1986, as amended, existing
and proposed Treasury regulations and administrative and
judicial interpretations, all as of the date of this prospectus
supplement, and all of which are subject to change,
retroactively or prospectively. The following summary assumes
that you hold our common stock as a capital asset (generally,
property held for investment). We undertake no obligation to
publicly update or otherwise revise this summary whether as a
result of new Treasury regulations, Code sections, judicial and
administrative interpretations or otherwise. The Code, Treasury
Regulations and judicial and administrative interpretations
thereof are also subject to various interpretations, and there
can be no guarantee that the Internal Revenue Service, or the
IRS, or U.S. courts will agree with the tax consequences
described in this summary. Each
non-U.S. holder
should consult a tax advisor regarding the U.S. federal,
state, local and
non-U.S. income
and other tax consequences of acquiring, holding and disposing
of shares of our common stock.
S-12
Dividends
We do not anticipate making cash distributions on our common
stock in the foreseeable future. In the event, however, that we
make distributions on our common stock, those payments will
constitute dividends for U.S. federal tax purposes to the
extent paid from our current or accumulated earnings and
profits, as determined under U.S. federal income tax
principles. To the extent those distributions exceed our current
and accumulated earnings and profits, they first will constitute
a return of capital and will reduce a
non-U.S. holders
basis in our common stock, but not below zero, and then will be
treated as gain from the sale of stock. Any dividend paid to a
non-U.S. holder
on our common stock that is not effectively connected with the
non-U.S. holders
conduct of a U.S. trade or business will generally be
subject to U.S. federal withholding tax at a rate of 30%,
or a lower rate under an applicable income tax treaty. You are
urged to consult your tax advisors regarding your entitlement to
benefits under a relevant income tax treaty. Generally, in order
for us to withhold tax at a lower treaty rate, you must provide
us with a
Form W-8BEN
(or other applicable form) certifying your eligibility for the
lower treaty rate.
If you claim the benefit of an applicable income tax treaty
rate, you generally will be required to satisfy applicable
certification and other requirements. However,
|
|
|
|
|
in the case of common stock held by a foreign partnership, the
certification requirement will generally be applied to partners
and the partnership will be required to provide certain
information;
|
|
|
|
in the case of common stock held by a foreign trust, the
certification requirement will generally be applied to the trust
or the beneficial owners of the trust depending on whether the
trust is a foreign complex trust, foreign
simple trust, or foreign grantor trust as
defined in the U.S. Treasury regulations; and
|
|
|
|
look-through rules apply for tiered partnerships, foreign simple
trusts and foreign grantor trusts.
|
A
non-U.S. holder
that is a foreign partnership or a foreign trust is urged to
consult its tax advisor regarding its status under these
U.S. Treasury regulations and the certification
requirements applicable to it.
If you are eligible for a reduced rate of U.S. federal
withholding tax under an income tax treaty, you may obtain a
refund or credit of any excess amounts withheld by filing an
appropriate claim for a refund on a timely basis with the
U.S. Internal Revenue Service.
If the dividend is effectively connected with your conduct of a
trade or business in the U.S. and, if an income tax treaty
applies, is attributable to a permanent establishment maintained
by you in the U.S., the dividend will generally be exempt from
U.S. federal withholding tax, provided that you supply us
with a properly executed
Form W-8ECI.
In this case, the dividend will be taxed on a net income basis
at the regular graduated rates and in the manner applicable to
U.S. persons and, if you are a foreign corporation, you may
be subject to an additional branch profits tax at a rate of 30%
or a lower rate as may be specified by an applicable income tax
treaty.
Gain on
Disposition of Common Stock
You generally will not be subject to U.S. federal income
tax on gain recognized on a disposition of our common stock
unless:
|
|
|
|
|
the gain is effectively connected with your conduct of a trade
or business in the U.S. and, if an income tax treaty
applies, is attributable to a permanent establishment maintained
by you in the U.S., in which case the gain will be taxed on a
net income basis at the regular graduated rates and in the
manner applicable to U.S. persons and, if you are a foreign
corporation, you may be subject to an additional branch profits
tax at a rate of 30% or a lower rate as may be specified by an
applicable income tax treaty;
|
|
|
|
you are an individual who holds our common stock as a capital
asset, are present in the U.S. for 183 days or more in
the taxable year of the disposition and meet other requirements,
in which case the gain will be taxed at a rate of 30%; or
|
S-13
|
|
|
|
|
we are or have been a United States real property holding
corporation, or USRPHC, for U.S. federal income tax
purposes at any time during the shorter of the five-year period
ending on the date of disposition and the period that you held
our common stock and certain other conditions are met, in which
case the gain will be taxed on a net income basis in the manner
described in the first bullet paragraph above.
|
Generally, a corporation is a USRPHC if the fair market value of
its United States real property interests equals or
exceeds 50% of the sum of the fair market value of its worldwide
real property interests plus its other assets used or held for
use in a trade or business. The tax relating to stock in a
USRPHC generally will not apply to a
non-U.S. holder
whose holdings, direct and indirect, at all times during the
applicable period, constituted 5% or less of our common stock,
provided that our common stock was regularly traded on an
established securities market in the calendar year of
disposition. We believe that we are not currently, and we do not
anticipate becoming in the future, a USRPHC for
U.S. federal income tax purposes.
Information
Reporting and Backup Withholding
Dividends paid to you are subject to information reporting and
may be subject to U.S. backup withholding. You will be
exempt from backup withholding if you provide a
Form W-8BEN
or otherwise meet documentary evidence requirements for
establishing that you are a
non-U.S. person
or otherwise establish an exemption.
The gross proceeds from the disposition of our common stock may
be subject to information reporting and backup withholding. If
you sell your common stock outside the U.S. through a
non-U.S. office
of a
non-U.S. broker
and the sales proceeds are paid to you outside the U.S., then
the U.S. backup withholding and information reporting
requirements generally (except as provided in the following
sentence) will not apply to that payment. However,
U.S. information reporting, but not backup withholding,
will apply to a payment of sales proceeds, even if that payment
is made outside the U.S., if you sell our common stock through a
non-U.S. office
of a broker that:
|
|
|
|
|
is a U.S. person;
|
|
|
|
derives 50% or more of its gross income in specific periods from
the conduct of a trade or business in the U.S.;
|
|
|
|
is a controlled foreign corporation for
U.S. tax purposes; or
|
|
|
|
is a foreign partnership, if at any time during its tax year,
one or more of its partners are U.S. persons who in the
aggregate hold more than 50% of the income or capital interests
in the partnership, or the foreign partnership is engaged in a
U.S. trade or business,
|
unless the broker has documentary evidence in its files that you
are a
non-U.S. person
and various other conditions are met or you otherwise establish
exemption.
If you receive payments of the proceeds of a sale of our common
stock through a U.S. office of a broker, the payment is
subject to both U.S. backup withholding and information
reporting unless you provide a
Form W-8BEN
certifying that you are a
non-U.S. person
or you otherwise establish an exemption.
You generally may obtain a refund or credit of any amount
withheld under the backup withholding rules that exceeds your
income tax liability by filing a refund claim with the
U.S. Internal Revenue Service.
Additional
Withholding Rules for Payments Made After December 31,
2012
The Hiring Incentives to Restore Employment Act of 2010 imposes
a withholding tax of 30% on certain types of payments made to
foreign financial institutions and certain other
non-U.S. entities
unless such entities satisfy additional certification,
information reporting and other specified requirements
(generally relating to ownership by U.S. persons of
interests in or accounts with those entities). Failure to comply
with the new reporting requirements could result in withholding
tax being imposed on payments to such entities of dividends on,
and proceeds from the sale of, our common stock. This
legislation is generally effective for
S-14
payments made after December 31, 2012. Prospective
investors should consult their own tax advisors regarding this
new legislation.
Federal
Estate Tax
Common stock owned or treated as owned by an individual who is a
non-U.S. person,
as specially defined for U.S. federal estate tax purposes,
at the time of death will be included in the individuals
gross estate for U.S. federal estate tax purposes, unless
an applicable estate tax or other treaty provides otherwise and,
therefore, may be subject to U.S. federal estate tax.
LEGAL
MATTERS
Hogan Lovells US LLP has passed upon certain legal matters with
respect to the common stock offered hereby. Certain legal
matters will be passed upon for the underwriter by Goodwin
Procter LLP.
EXPERTS
The consolidated financial statements of NxStage Medical, Inc.
appearing in NxStage Medical Inc.s Annual Report
(Form 10-K)
for the year ended December 31, 2009, and the effectiveness
of NxStage Medical Inc.s internal control over financial
reporting as of December 31, 2009 have been audited by
Ernst & Young LLP, independent registered public
accounting firm, as set forth in their reports thereon, included
therein, and incorporated herein by reference. Such consolidated
financial statements are incorporated herein by reference in
reliance upon such reports given on the authority of such firm
as experts in accounting and auditing.
S-15
Common Stock
Debt Securities
Preferred Stock
Warrants
We may, from time to time, offer, issue and sell senior or
subordinated debt securities, preferred stock, common stock, or
warrants to purchase our debt securities, preferred stock or
common stock. The debt securities, preferred stock and warrants
we may offer may be convertible into or exercisable or
exchangeable for debt, common or preferred stock or other
securities of the Company or debt or equity securities of one or
more other entities. We refer to our senior or subordinated debt
securities, preferred stock, common stock, and warrants
collectively as the securities. We may offer the
securities separately or together, in separate series or classes
and in amounts, at prices and on terms described in one or more
supplements to this prospectus. In addition, this prospectus may
be used to offer securities for the account of persons other
than us.
This prospectus describes some of the general terms that may
apply to the securities we or any selling securityholders may
offer and sell. Each time we or any selling securityholders
offer securities pursuant to this prospectus, we or any selling
securityholders will provide one or more supplements to this
prospectus or free writing prospectuses that contain specific
information about the offering and the terms of any securities
being sold. Before investing, you should carefully read this
prospectus and any related prospectus supplement. Prospectus
supplements or free writing prospectuses may also add, update or
change information contained in this prospectus.
We or any selling securityholder may offer and sell these
securities to or through agents, underwriters, dealers or
directly to purchasers, on a continuous or delayed basis. The
names of any agents, underwriters or dealers and the terms of
the arrangements with such entities will be stated in the
applicable prospectus supplement.
Our common stock is traded on the Nasdaq Global Market under the
symbol NXTM.
You should read carefully this prospectus, the documents
incorporated by reference in this prospectus and any prospectus
supplement before you invest. Please see Risk
Factors on page 2 for more information.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this
prospectus. Any representation to the contrary is a criminal
offense.
The date of this prospectus is November 17, 2010
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
18
|
|
|
|
|
19
|
|
|
|
|
20
|
|
|
|
|
20
|
|
|
|
|
20
|
|
ABOUT
THIS PROSPECTUS
This prospectus is a part of a registration statement that we
filed with the Securities and Exchange Commission (the
SEC) utilizing a shelf registration
process. Under this shelf registration process, we or any
selling securityholder may sell any combination of the
securities described in this prospectus in one or more offerings
from time to time. This prospectus provides you with a general
description of the securities we or any selling securityholder
may offer. Each time we or any selling securityholder sell
securities pursuant to this prospectus, we or such selling
securityholder will provide a prospectus supplement or free
writing prospectus that will contain specific information about
the terms of that offering. The prospectus supplement or free
writing prospectus may also add, update or change information
contained in this prospectus. Therefore, if there is any
inconsistency between the information in this prospectus and the
prospectus supplement, you should rely on the information in the
prospectus supplement. You should read both this prospectus and
any prospectus supplement together with the additional
information described under the headings Where You Can
Find More Information and Incorporation of Certain
Information by Reference, and any free writing prospectus
that we prepare and distribute.
Neither we nor any selling securityholder have authorized any
dealer, salesman or other person to give any information or to
make any representation other than those contained or
incorporated by reference in this prospectus, any accompanying
supplement to this prospectus or any free writing prospectus
that may be incorporated by reference into this prospectus or
any prospectus supplement or any documents incorporated by
reference into this prospectus or any prospectus supplement. You
must not rely upon any information or representation not
contained or incorporated by reference in this prospectus or any
accompanying prospectus supplement or any free writing
prospectus. Neither this prospectus nor any accompanying
prospectus supplement nor any free writing prospectus constitute
an offer to sell or the solicitation of an offer to buy any
securities other than the registered securities to which they
relate, nor do this prospectus or any accompanying prospectus
supplement or any free writing prospectus constitute an offer to
sell or the solicitation of an offer to buy securities in any
jurisdiction to any person to whom it is unlawful to make such
offer or solicitation in such jurisdiction. You should not
assume that the information contained in this prospectus or any
accompanying prospectus supplement or any free writing
prospectus or any other offering materials is accurate on any
date subsequent to the date set forth on the front of such
document or that any information we have incorporated by
reference is correct on any date subsequent to the date of the
document incorporated by reference, even though this prospectus
or any accompanying prospectus supplement or any free writing
prospectus is delivered or securities are sold on a later date.
Unless the context otherwise requires or as otherwise expressly
stated, references in this prospectus to the
Company, NxStage, we,
us and our and similar terms refer to
NxStage Medical, Inc and our subsidiaries on a consolidated
basis.
i
PROSPECTUS
SUMMARY
This summary contains a general summary of the information
contained in this prospectus. It may not include all the
information that is important to you. You should read the entire
prospectus, the prospectus supplement delivered with the
prospectus, if any, and the documents incorporated by reference
before making an investment decision.
Our
Company
We are a medical device company that develops, manufactures and
markets innovative products for the treatment of kidney failure,
fluid overload and related blood treatments and procedures. Our
primary product, the NxStage System One, or System One, was
designed to satisfy an unmet clinical need for a system that can
deliver the therapeutic flexibility and clinical benefits
associated with traditional dialysis machines in a smaller,
portable, easy-to-use form that can be used by healthcare
professionals and trained lay users alike in a variety of
settings, including patient homes, as well as more traditional
care settings such as hospitals and dialysis clinics. Given its
design, the System One is particularly well-suited for home
hemodialysis and a range of dialysis therapies including more
frequent, or daily, dialysis, which clinical
literature suggests provides patients better clinical outcomes
and improved quality of life.
The System One is cleared by the United States Food and Drug
Administration, or FDA, for home hemodialysis as well as
hospital and clinic-based dialysis. We also sell needles and
blood tubing sets primarily to dialysis clinics for the
treatment of end-stage renal disease, or ESRD, which we refer to
as the in-center market. We believe our largest future product
market opportunity is for our System One used in the home
hemodialysis market, or home market, for the treatment of ESRD.
We report the results of our operations in two segments: System
One and In-Center. We distribute our products in three markets:
home, critical care and in-center. In the System One segment we
derive our revenues from the sale and rental of equipment and
the sale of disposable products in the home and critical care
markets. We define the home market as the market devoted to the
treatment of ESRD patients in the home and the critical care
market as the market devoted to the treatment of hospital-based
patients with acute kidney failure or fluid overload. In the
In-Center segment, we derive our revenues from the sale of
needles and blood tubing sets primarily used for in-center
dialysis treatments.
Within the System One segment, we offer a similar technology
platform of the System One for the home and critical care
markets with different features. The FDA has cleared the System
One for hemodialysis, hemofiltration and ultrafiltration. We
offer primarily needles and blood tubing sets in the In-Center
segment. Our products are predominantly used by our customers to
treat patients suffering from ESRD or acute kidney failure. We
have marketing and sales efforts dedicated to each market,
although nearly all sales in the In-Center segment are made
through distributors.
We were incorporated in Delaware in 1998 under the name QB
Medical, Inc, and later changed our name to NxStage Medical,
Inc. Financial results in each of our two reportable segments,
including information about revenues from customers, measures of
profit and loss, and total assets are discussed in our annual
consolidated financial statements that are incorporated by
reference herein.
The address of our principal executive office is 439 South Union
Street, Fifth Floor, Lawrence, Massachusetts 01843 and our
telephone number is
(978) 687-4700.
Our internet website is www.nxstage.com. We make our electronic
filings with the Securities Exchange Commission (the
SEC), including our annual reports on
Form 10-K,
quarterly reports on
Form 10-Q,
current reports on
Form 8-K
and amendments to these reports available on our website free of
charge as soon as practicable after we file or furnish them with
the SEC. Information on our website is not a part of, or
incorporated by reference into, this prospectus.
1
RISK
FACTORS
Investing in our securities involves a high degree of risk. You
should carefully consider and evaluate all of the information
contained in this prospectus, any accompanying prospectus
supplement, and in the documents we incorporate by reference in
this prospectus before you decide to purchase our securities. In
particular, you should carefully consider and evaluate the risks
and uncertainties described in Part I
Item 1A. Risk Factors of our most recent
Form 10-K,
as updated by the additional risks and uncertainties set forth
in other filings we make with the SEC or any accompanying
prospectus supplement. Any of the risks and uncertainties set
forth therein could materially and adversely affect our
business, results of operations and financial condition, which
in turn could materially and adversely affect the trading price
or value of our securities. As a result, you could lose all or
part of your investment.
WHERE YOU
CAN FIND MORE INFORMATION
We are currently subject to the reporting requirements of the
Securities Exchange Act of 1934, as amended (the Exchange
Act) and in accordance therewith file periodic reports,
proxy statements and other information with the Securities and
Exchange Commission. You may read and copy (at prescribed rates)
any such reports, proxy statements and other information at the
SECs Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the operation of the public reference
room. Our SEC filings will also be available to you on the
SECs website at
http://www.sec.gov
and in the Investors section of our website at
http://www.nxstage.com.
Our website and the information contained on that site, or
connected to that site, are not incorporated into and are not a
part of this prospectus.
We have filed with the SEC a registration statement on
Form S-3
with respect to the securities offered hereby. This prospectus
does not contain all the information set forth in the
registration statement, parts of which are omitted in accordance
with the rules and regulations of the SEC. For further
information with respect to us and the securities offered
hereby, reference is made to the registration statement.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
We incorporate information into this prospectus by reference,
which means that we disclose important information to you by
referring you to another document filed separately with the SEC.
The information incorporated by reference is deemed to be part
of this prospectus, except to the extent superseded by
information contained in this prospectus. This prospectus
incorporates by reference the documents set forth below, the
file number for each of which is
000-51567,
that have been previously filed with the SEC:
|
|
|
|
|
our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2009;
|
|
|
|
our Proxy Statement for our 2010 Annual Meeting of Stockholders,
filed with the SEC on April 29, 2010;
|
|
|
|
our Quarterly Reports on
Form 10-Q
for the quarterly periods ended March 31, 2010,
June 30, 2010 and September 30, 2010;
|
|
|
|
our Current Reports on
Form 8-K
filed with the SEC on March 5, 2010, June 1, 2010 and
July 23, 2010 (but not including the information under, or
incorporated by reference into, Item 7.01 of the
Form 8-K
filed on July 23, 2010).
|
|
|
|
the description of our common stock, par value $0.001 per share,
contained in our Registration Statement on
Form 8-A,
filed pursuant to Section 12 of the Exchange Act on
October 7, 2005 (Registration
No. 000-51567),
including any amendments or reports filed to update such
information.
|
In addition, all documents that we file with the SEC pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act
after the date of the initial registration statement of which
this prospectus is a part and all such documents that we file
with the SEC after the date of this prospectus and before the
termination of the offering of our securities shall be deemed
incorporated by reference into this prospectus and to be a part
of
2
this prospectus from the respective dates of filing such
documents. Unless specifically stated to the contrary, none of
the information that we disclose under Items 2.02 or 7.01
of any Current Report on
Form 8-K
that we may from time to time furnish to the SEC will be
incorporated by reference into, or otherwise included in, this
prospectus.
Any statement contained in a document incorporated by reference
in this prospectus shall be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement
contained in this prospectus or in any other subsequently filed
document that also is or is deemed to be incorporated by
reference in this prospectus modifies or supersedes such
statement. Any statement so modified or superseded shall not be
deemed, except as so modified or superseded, to constitute a
part of this prospectus.
You may obtain copies of any of these filings by contacting us
at the address and telephone number indicated below or by
contacting the SEC as described above under the section entitled
Where You Can Find More Information. Documents
incorporated by reference are available from us without charge,
excluding all exhibits unless an exhibit has been specifically
incorporated by reference into this prospectus, by requesting
them in writing or by telephone at:
NxStage
Medical, Inc.
Attention: Corporate Secretary
439 South Union Street,
5th
Floor
Lawrence, MA 01843
(978) 687-4700
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains or incorporates by reference
forward-looking statements within the meaning of
Section 27A of the Securities Act and Section 21E of
the Exchange Act. Forward-looking statements may include the
words may, will, estimate,
intend, continue, believe,
expect, plan or anticipate
and other similar words. Our forward-looking
statements include, but are not limited to, statements
regarding:
|
|
|
|
|
our business, operations and financial condition;
|
|
|
|
the market adoption of our products in the United States and
internationally;
|
|
|
|
the growth of the home, critical care and in-center dialysis
markets in general and the home hemodialysis market in
particular;
|
|
|
|
the development and commercialization of our products;
|
|
|
|
changes in the historical purchasing patterns and preferences of
our major customers, including DaVita Inc.;
|
|
|
|
the adequacy of our funding;
|
|
|
|
our ability to sustain positive cash flows;
|
|
|
|
our need for and our ability to obtain additional funding;
|
|
|
|
whether and when we might achieve improvements to our gross
margins and operating expenses;
|
|
|
|
expectations with respect to our operating expenses and
achieving our business plan;
|
|
|
|
expectations with respect to achieving profitable operations;
|
|
|
|
expectations with respect to achieving improvements in product
reliability;
|
|
|
|
the timing and success of the submission, acceptance and
approval of regulatory filings and the impact of any changes in
the regulatory environment with respect to our products or
business;
|
|
|
|
the scope of patent protection with respect to our products;
|
|
|
|
the timing and success of competitive product offerings;
|
3
|
|
|
|
|
expectations with respect to the clinical findings of our
FREEDOM study;
|
|
|
|
the impact of future changes to reimbursement for chronic
dialysis treatments and the impact current economic conditions
on our business; and
|
|
|
|
assumptions relating to the foregoing.
|
Our future financial condition and results of operations, as
well as any forward-looking statements, are subject to change
and are subject to inherent risks and uncertainties, such as
those disclosed in this prospectus. Important risks and factors
that could cause our actual results to be materially different
from our expectations include the factors that are disclosed in
Part I Item 1A. Risk Factors
of our most recent Annual Report on
Form 10-K
as updated by the additional risks and uncertainties set forth
in other filings we make with the SEC or any accompanying
prospectus supplement. You should read these factors and the
other cautionary statements made in this prospectus as being
applicable to all related forward-looking statements wherever
they appear in this prospectus. Each forward-looking statement
contained in this prospectus reflects managements view
only as of the date on which that forward-looking statement was
made. We undertake no obligation to update forward-looking
statements or publicly release the result of any revisions to
them to reflect events or circumstances after the date of this
prospectus or to reflect the occurrence of unanticipated events.
USE OF
PROCEEDS
Any accompanying prospectus supplement will set forth our
intended use of the net proceeds from the sale of our securities
offered by us, which could include, among other uses, general
corporate purposes.
Unless otherwise set forth in a prospectus supplement, we will
not receive any proceeds in the event that securities are sold
by a selling securityholder.
RATIO OF
EARNINGS TO FIXED CHARGES
The table below presents the ratio of earnings to combined fixed
charges and preferred stock dividends and the coverage
deficiency for the last five fiscal years and the nine months
ended September 30, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Months Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
Year Ended December 31
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Deficiency of earnings to combined preference dividends and
fixed charges (in thousands)
|
|
$
|
(25,419
|
)
|
|
$
|
(43,467
|
)
|
|
$
|
(51,211
|
)
|
|
$
|
(58,396
|
)
|
|
$
|
(39,630
|
)
|
|
$
|
(24,480
|
)
|
For the nine months ended September 30, 2010, and the years
ended December 31, 2009, 2008, 2007, 2006 and 2005,
earnings are inadequate to cover fixed charges and the dollar
amount of the deficiency is disclosed in the above table, in
thousands.
For purposes of calculating this deficiency, earnings consist of
net loss before fixed charges. Fixed charges include interest
expense, including amortization of deferred financing costs, and
the portion of rent expense which we believe is representative
of the interest component of rental expense.
This information should be read in conjunction with our
consolidated financial statements and the accompanying notes
incorporated by reference in this prospectus.
4
DESCRIPTION
OF OUR COMMON STOCK
The following description of our common stock and the provisions
of our restated certificate of incorporation and amended and
restated bylaws are summaries and are qualified in their
entirety by reference to our restated certificate of
incorporation and amended and restated bylaws, which are filed
as exhibits to the registration statement that includes this
prospectus. The General Corporation Law of the State of
Delaware, or the DGCL, may also affect the terms of our common
stock.
Authorized
and Outstanding Common Stock
Our restated certificate of incorporation provides that we have
authority to issue 100,000,000 shares of our common stock,
par value $0.001 per share. As of September 30, 2010, there
were 49,310,143 shares of common stock issued and
49,105,809 shares of common stock outstanding, and there
were outstanding warrants to purchase up to an additional
7,133,329 shares of our common stock and options to
purchase 7,969,546 shares of our common stock.
Listing
Our common stock is listed on The Nasdaq Global Market under the
symbol NXTM.
Dividends
Our board of directors may authorize, and we may make,
distributions to our common stockholders, subject to any
restriction in our restated certificate of incorporation and to
those limitations prescribed by law. However, we have never paid
or declared cash dividends on our common stock or any other
securities. We do not anticipate paying cash dividends in the
foreseeable future. In addition, certain of our loan agreements
restrict our ability to pay dividends.
Fully
Paid and Non-Assessable
All shares of our outstanding common stock are fully paid and
non-assessable.
Voting
Rights
Each share of our common stock is entitled to one vote in each
matter submitted to a vote at a meeting of stockholders
including in all elections for directors; stockholders are not
entitled to cumulative voting in the election for directors. Our
stockholders may vote either in person or by proxy.
Preemptive
and Other Rights
Holders of our common stock have no preemptive rights and have
no other rights to subscribe for additional securities of our
company under Delaware law. Nor does the common stock have any
conversion rights or rights of redemption (or, if any such
rights have been granted in relation to the common stock, any
such rights have been waived). Upon liquidation, all holders of
our common stock are entitled to participate pro rata in our
assets available for distribution, subject to the rights of any
class of preferred stock then outstanding.
Stockholder
Action; Meetings; Advance Notice Requirements
Our restated certificate of incorporation and our amended and
restated bylaws provide that any action required or permitted to
be taken by our stockholders at an annual meeting or special
meeting of stockholders may only be taken if it is properly
brought before such meeting and may not be taken by written
action in lieu of a meeting. Our restated certificate of
incorporation and our amended and restated bylaws also provide
that, except as otherwise required by law, special meetings of
the stockholders can only be called by our chairman of the
board, our president or our board of directors. In addition, our
amended and restated bylaws establish an advance notice
procedure for stockholder proposals to be brought before an
annual meeting of stockholders, including proposed nominations
of candidates for election to the board of directors.
Stockholders at an annual meeting may only consider proposals or
nominations specified in the notice of meeting or brought before
the
5
meeting by or at the direction of the board of directors, or by
a stockholder of record on the record date for the meeting, who
is entitled to vote at the meeting and who has delivered timely
written notice in proper form to our secretary of the
stockholders intention to bring such business before the
meeting. These provisions could have the effect of delaying
until the next stockholder meeting stockholder actions that are
favored by the holders of a majority of our outstanding voting
securities.
Super-Majority
Voting
The DGCL provides generally that the affirmative vote of a
majority of the shares entitled to vote on any matter is
required to amend a corporations certificate of
incorporation or bylaws, unless a corporations certificate
of incorporation or bylaws, as the case may be, requires a
greater percentage. Our amended and restated bylaws may be
amended or repealed by a majority vote of our board of directors
or the affirmative vote of the holders of at least 75% of the
votes that all our stockholders would be entitled to cast in any
annual election of directors. In addition, the affirmative vote
of the holders of at least 75% of the votes that all our
stockholders would be entitled to cast in any election of
directors is required to amend or repeal or to adopt any
provisions inconsistent with any of the provisions of our
restated certificate of incorporation described above.
Transfer
Agent and Registrar
The transfer agent and registrar for our common stock is
Computershare.
Limitations
of Director Liability
Delaware law authorizes corporations to limit or eliminate the
personal liability of directors to corporations and their
stockholders for monetary damages for breach of directors
fiduciary duty of care. Although Delaware law does not change
directors duty of care, it enables corporations to limit
available relief to equitable remedies such as injunction or
rescission. Our restated certificate of incorporation limits the
liability of directors to us and our stockholders to the full
extent permitted by Delaware law. Specifically, directors are
not personally liable for monetary damages to us or our
stockholders for breach of the directors fiduciary duty as
a director, except to the extent that the DGCL prohibits the
elimination or limitation of liability of directors for breaches
of fiduciary duty.
Indemnification
To the maximum extent permitted by law, our restated certificate
of incorporation provides for mandatory indemnification of
directors and officers against any expense, judgment, fine and
amounts paid in settlement actually and reasonably incurred by
or on behalf of the indemnified party, if he or she acts in good
faith and in a manner which he or she reasonably believed to be
in, or not opposed to, the best interests of the Company, and,
with respect to any criminal action or proceeding, has no
reasonable cause to believe his or her conduct was unlawful. In
addition, we must advance or reimburse directors and officers
for expenses they incur in connection with indemnifiable claims.
We also maintain directors and officers liability
insurance.
DESCRIPTION
OF DEBT SECURITIES
The following description sets forth certain general provisions
of the debt securities that may be offered by means of this
prospectus. The particular terms of the debt securities being
offered and the extent to which the general provisions described
below apply will be described in a prospectus supplement
relating to the debt securities.
Any senior debt securities offered by means of this prospectus
will be issued under a senior debt securities indenture, as
amended or supplemented from time to time, which we refer to as
the Senior Debt Securities Indenture, between
NxStage and such trustee as may be appointed by NxStage. Any
subordinated debt securities offered by means of this prospectus
will be issued under a separate subordinated debt securities
indenture, as amended or supplemented from time to time, which
we refer to as the Subordinated Debt
6
Securities Indenture, between NxStage and such trustee as
may be appointed by NxStage. The Senior Debt Securities
Indenture and the Subordinated Debt Securities Indenture are
referred to in this prospectus individually as the
Indenture and collectively as the
Indentures. A form of the Senior Debt Securities
Indenture and a form of the Subordinated Debt Securities
Indenture have been filed as exhibits to the Registration
Statement of which this prospectus is a part and will be
available for inspection at the corporate trust office of the
trustee or as described below under Where to Find
Additional Information.
The Indentures are and will be subject to and governed by the
Trust Indenture Act of 1939. The description of the
Indentures set forth below assumes that NxStage has entered into
both of the Indentures. NxStage will execute and deliver one or
both of the Indentures when and if it issues debt securities.
The statements made in this prospectus relating to the
Indentures and the debt securities to be issued under the
Indentures are summaries of some provisions of the Indentures
and such debt securities. The summaries do not purport to be
complete and are subject to, and are qualified in their entirety
by reference to, all provisions of the Indentures and such debt
securities. Unless otherwise specified, capitalized terms used
but not defined in this prospectus have the meanings set forth
in the Indentures.
General
The debt securities offered by means of this prospectus will be
direct obligations of NxStage. Senior debt securities will rank
equally in right of payment with other senior and unsubordinated
debt of NxStage that may be outstanding from time to time, and
will rank senior in right of payment to all subordinated debt
securities of NxStage that may be outstanding from time to time.
Subordinated debt securities will be subordinated in right of
payment to the prior payment in full of the senior debt of
NxStage, as described under Subordination below.
Each Indenture provides that debt securities may be issued
without limit as to aggregate principal amount, in one or more
series, in each case as established from time to time in or
pursuant to authority granted by one or more resolutions of the
board of directors of NxStage or as established in one or more
indentures supplemental to the Indenture. All debt securities of
one series need not be issued at the same time and, unless
otherwise provided, a series may be reopened, without the
consent of the holders of the debt securities of such series,
for issuances of additional debt securities of such series.
Each Indenture provides that there may be more than one trustee
thereunder, each with respect to one or more series of debt
securities. Any trustee under either Indenture may resign or be
removed with respect to one or more series of debt securities,
and a successor trustee will be appointed by NxStage, by or
pursuant to a resolution adopted by the board of directors, to
act with respect to such series. If two or more persons are
acting as trustee with respect to different series of debt
securities, each such trustee will be a trustee of a trust under
the applicable Indenture separate and apart from the trust
administered by any other trustee thereunder, and, except as
otherwise indicated herein or therein, any action described to
be taken by the trustee may be taken by each such trustee with
respect to, and only with respect to, the one or more series of
debt securities for which it is trustee under the Indenture.
The supplement to this prospectus relating to the series of debt
securities being offered will contain information on the
specific terms of such debt securities, including:
(1) the title of such series of debt securities;
(2) the classification of such debt securities as senior
debt securities or subordinated debt securities;
(3) the aggregate principal amount of such debt securities
and any limit on such aggregate principal amount;
(4) the percentage of the principal amount of such debt
securities that will be issued and, if other than the entire
principal amount thereof, the portion of the principal amount
thereof payable upon declaration of acceleration of the maturity
thereof or, if applicable, the portion of the principal amount
thereof that is convertible in accordance with the provisions of
the applicable Indenture, or the method by which such portion
shall be determined;
7
(5) the terms and conditions, if any, upon which such debt
securities may be convertible into or exchangeable for other
securities of NxStage or securities of another person and the
terms and conditions upon which such conversion or exchange will
be effected, including, without limitation, whether such debt
securities are convertible into or exchangeable for common stock
or other capital stock of NxStage or such other person, the
initial conversion price or rate (or manner of calculation
thereof), the portion that is convertible or exchangeable or the
method by which any such portion shall be determined, the
conversion period, provisions as to whether conversion or
exchange will be at the option of the holders, NxStage, or such
other person the events requiring an adjustment of the
conversion or exchange price and provisions affecting conversion
or exchange in the event of the redemption of such debt
securities;
(6) the date or dates, or the method for determining such
date or dates, on which the principal of such debt securities
will be payable;
(7) the rate or rates, or the method by which such rate or
rates shall be determined, at which such debt securities will
bear interest, if any;
(8) the date or dates, or the method for determining such
date or dates, from which any such interest will accrue, the
date or dates on which any such interest will be payable, the
regular record dates for the interest payment dates, or the
method by which the regular record dates are to be determined,
the person to whom such interest will be payable, and the basis
upon which interest shall be calculated if other than that of a
360-day year
of twelve
30-day
months;
(9) the place or places where the principal of (and
premium, if any) and interest and any additional amounts related
to specified taxes imposed on the holders of such debt
securities, or Additional Amounts, on such debt
securities will be payable, where such debt securities may be
surrendered for conversion or registration of transfer or
exchange, and where notices or demands to or upon NxStage in
respect of such debt securities and the applicable Indenture may
be served;
(10) the date or dates on which, or period or periods
within which, the price or prices at which, the currency in
which, and the other terms and conditions upon which such debt
securities may be redeemed, in whole or in part, at the option
of NxStage, if NxStage is to have such an option;
(11) the obligation, if any, of NxStage to redeem, repay or
purchase such debt securities pursuant to any sinking fund or
analogous provision or at the option of a holder thereof, and
the date or dates on which, or period or periods within which,
the price or prices at which, the currency or currencies in
which, and the other terms and conditions upon which such debt
securities will be redeemed, repaid or purchased, in whole or in
part, pursuant to such obligation;
(12) if other than U.S. dollars, the foreign currency
or currencies in which such debt securities are denominated and
payable, which may be a foreign currency or units of two or more
foreign currencies or a composite currency or currencies, and
the terms and conditions relating thereto;
(13) whether the amount of payments of principal of (and
premium, if any) or interest on such debt securities may be
determined with reference to an index, formula or other method
(which index, formula or method may, but need not be, based on
one or more currencies, commodities, equity indices or other
indices) and the manner in which such amounts shall be
determined;
(14) whether such debt securities will be secured or
unsecured and if secured, the nature of the collateral securing
the debt securities;
(15) whether such debt securities will be issued in the
form of one or more global securities and whether such global
securities are to be issuable in a temporary global form or
permanent global form;
(16) any deletions from, modifications of or addition to
the events of default or covenants of NxStage with respect to
such debt securities, whether or not such events of default or
covenants are consistent with the events of default or covenants
set forth in the applicable Indenture;
(17) whether the principal of (and premium, if any) or
interest or Additional Amounts, if any, on such debt securities
are to be payable, at the election of NxStage or a holder, in
one or more currencies
8
other than that in which such debt securities are payable in the
absence of the making of such an election, the date or dates on
which, or period or periods within which, and the terms and
conditions upon which, such election may be made, and the time
and manner of, and identity of the exchange rate agent with
responsibility for, determining the exchange rate between the
currency or currencies in which such debt securities are payable
in the absence of the making of such an election and the
currency or currencies in which such debt securities are to be
payable upon the making of such an election;
(18) whether such debt securities will be issued in
certificated or book-entry form and if in certificated form, the
form and/or
terms of the certificates or other documents and the other
conditions to be satisfied;
(19) whether such debt securities will be in registered or
bearer form, or both, the terms, if any, on which securities in
registered form and in bearer form may be exchanged for each
other, and, if in registered form, the denominations thereof if
other than $1,000 and any integral multiple thereof and, if in
bearer form, the denominations thereof if other than $5,000 and
terms and conditions relating thereto;
(20) the applicability, if any, of the defeasance and
covenant defeasance provisions of the applicable Indenture, and
any provisions in modification of, in addition to or in lieu of
such provisions;
(21) if such debt securities are to be issued upon the
exercise of warrants, the time, manner and place for such debt
securities to be authenticated and delivered;
(22) whether and to what extent such debt securities will
be guaranteed by a guarantor and the identity of such guarantor;
(23) provisions, if any, granting special rights to the
holders of such debt securities upon the occurrence of such
events as may be specified;
(24) whether and under what circumstances NxStage will pay
Additional Amounts as contemplated in the applicable Indenture
on such debt securities to any holder thereof who is not a
U.S. person and, if so, whether NxStage will have the
option to redeem such debt securities in lieu of making such
payment and the terms of any such option;
(25) the name of the applicable trustee and the address of
its corporate trust office and, if other than the trustee, the
name of each security registrar and paying agent;
(26) the date as of which any debt securities in bearer
form and any temporary global security shall be dated if other
than the date of original issuance; and
(27) any other terms of such debt securities not
inconsistent with the provisions of the applicable Indenture.
Debt securities offered by means of this prospectus may be
original issue discount securities, in that they provide for
less than the entire principal amount thereof to be payable upon
declaration of acceleration of the maturity thereof. If they are
original issue discount securities, the special
U.S. federal income tax, accounting and other
considerations applicable to such securities will be described
in the applicable prospectus supplement.
Neither Indenture contains any other provisions that would limit
the ability of NxStage to incur indebtedness or that would
afford holders of debt securities protection in the event of a
highly leveraged or similar transaction involving NxStage or in
the event of a change of control of NxStage.
The rights of NxStage and its creditors, including holders of
debt securities offered by means of this prospectus, to
participate in the assets of NxStages subsidiaries upon
the liquidation or recapitalization of such subsidiaries or
otherwise will be subject to the prior claims of such
subsidiaries respective secured and unsecured creditors
(except to the extent that claims of NxStage itself as a
creditor may be recognized).
9
Denominations,
Interest, Registration and Transfer
Unless otherwise described in the applicable prospectus
supplement, the debt securities of any series offered by means
of this prospectus in registered form will be issuable in
denominations of $1,000 and integral multiples thereof and in
bearer form will be issuable in denominations of $5,000, except
that securities issued in global form may be of any denomination.
Unless otherwise specified in the applicable prospectus
supplement, the principal of (and premium, if any) and interest
and any Additional Amounts on any series of debt securities
offered by means of this prospectus will be payable at the
office or agency designated by NxStage in accordance with the
Indenture. Unless otherwise specified in the applicable
prospectus supplement, payment of interest on any such series of
debt securities to the holders thereof on any regular record
date will be made (1) to each person entitled thereto
having an aggregate principal amount of debt securities of
$1,000,000 or less, by check mailed to the address of such
person as it appears in the security register and (2) to
each person entitled thereto having an aggregate principal
amount of debt securities of more than $1,000,000, either by
check mailed to such person or, upon application by any such
person to the security registrar not later than the applicable
record date, by wire transfer in immediately available funds to
such persons account within the United States. Such an
application will remain in effect until such person notifies the
security registrar in writing to the contrary. In the case of
any securities issued in bearer form, payment of interest may be
made, at NxStages option, by transfer to an account
maintained by the payee with a bank located outside the United
States.
Unless otherwise specified in the applicable prospectus
supplement, the principal of (and premium, if any) and interest
and any Additional Amounts on any debt securities in global form
registered in the name of or held by The Depository
Trust Company, or DTC, or its nominee will be
payable to DTC or its nominee as the registered holder thereof.
Unless otherwise specified in the applicable prospectus
supplement, any interest not punctually paid or duly provided
for on any interest payment date with respect to a debt security
offered by means of this prospectus, or Defaulted
Interest, will forthwith cease to be payable to the holder
on the applicable regular record date and may either be paid to
the person in whose name such debt security is registered at the
close of business on a special record date, which we refer to as
the Special Record Date, for the payment of such
Defaulted Interest to be fixed by the applicable trustee, with
notice thereof to be given to the holder of such debt security
not less than 10 days prior to such Special Record Date, or
may be paid at any time in any other lawful manner, all as more
completely described in the applicable Indenture.
Subject to certain limitations imposed upon debt securities
issued in book-entry form, the debt securities of any series
offered by means of this prospectus will be exchangeable for
other debt securities in registered form of the same series and
of a like aggregate principal amount and tenor of any authorized
denominations upon surrender of such debt securities at the
corporate trust office of the applicable trustee or at an office
or agency established by NxStage in accordance with the
Indenture. In addition, subject to certain limitations imposed
upon debt securities issued in book-entry form, the debt
securities of any series offered by means of this prospectus may
be surrendered for registration of transfer thereof at the
corporate trust office of the trustee or other office or agency
referred to above. Every debt security surrendered for
registration of transfer or exchange shall be duly endorsed or
accompanied by a written instrument of transfer. No service
charge will be made for any registration of transfer or exchange
of any debt securities (other than specified exchanges not
involving a transfer), but NxStage may require payment of a sum
sufficient to cover any tax or other governmental charge payable
in connection therewith. If the applicable prospectus supplement
refers to any transfer agent (in addition to the trustee)
initially designated by NxStage with respect to any series of
debt securities, NxStage at any time may rescind the designation
of any such transfer agent or approve a change in the location
through which any such transfer agent acts, except that NxStage
will be required to maintain a transfer agent in each place of
payment for such series. NxStage at any time may designate
additional transfer agents with respect to any series of debt
securities offered by means of this prospectus.
NxStage may change the paying agent or security registrar under
either Indenture without prior notice to the holders of the
series of debt securities outstanding thereunder, and also may
act as the paying agent and security registrar for such series.
10
Neither NxStage nor the trustee for any series of debt
securities offered by means of this prospectus will be required
to:
|
|
|
|
|
issue, register the transfer of or exchange debt securities of
any series during a period beginning at the opening of business
15 days before any selection of debt securities of that
series to be redeemed and ending at the close of business on the
day of mailing of the relevant notice of redemption (or, in the
case of bearer securities, the date of first publication of such
notice);
|
|
|
|
register the transfer of or exchange any debt security, or
portion thereof, called for redemption, except the unredeemed
portion of any debt security being redeemed in part;
|
|
|
|
exchange debt securities in bearer form selected for redemption
except for an exchange for any debt security that is registered
in the security register of that series and of like
tenor; or
|
|
|
|
issue, register the transfer of or exchange any debt security
which has been surrendered for repayment at the option of the
holder, except the portion, if any, of such debt security not to
be so repaid.
|
Covenants
Existence. Except as described under
Consolidation, Merger and Sale of Assets below,
NxStage and each guarantor, if any, of the debt securities is
required to do or cause to be done all things necessary to
preserve and keep in full force and effect its corporate
existence, rights and franchises, except that (a) neither
NxStage nor any such guarantor is obligated to preserve any
right or franchise and (b) none of the guarantors is
obligated to preserve its existence, in either case if NXStage
determines that the preservation thereof is no longer desirable
in the conduct of its business and that the loss thereof is not
disadvantageous in any material respect to the holders of the
debt securities issued under the Indenture.
Maintenance of Properties. NxStage will cause,
and will cause each of its subsidiaries to cause, all of its
material properties used or useful in the conduct of its
business or the business of any subsidiary to be maintained and
kept in good condition, repair and working order and supplied
with all necessary equipment and will cause to be made all
necessary repairs, renewals, replacements, betterments and
improvements thereof, all as in the judgment of NxStage may be
necessary so that the business carried on in connection
therewith may be properly and advantageously conducted at all
times, except that NxStage and any subsidiary may discontinue
the operation and maintenance of any such properties if it
determines that the discontinuance thereof is no longer
desirable in the conduct of its business and is not
disadvantageous in any material respect to the holders of the
debt securities issued under the Indenture.
Payment of Taxes and Other Claims. NxStage
will pay or discharge or cause to be paid or discharged, before
the same shall become delinquent, (1) all material taxes,
assessments and governmental charges levied or imposed upon it
or any subsidiary or upon the income, profits or property of
NxStage or any subsidiary, and (2) all material lawful
claims for labor, materials and supplies which, if unpaid, might
by law become a lien upon the property of NxStage or any
subsidiary, unless such lien would not have a material adverse
effect upon such property, except that NxStage will not be
required to pay or discharge or cause to be paid or discharged
any such tax, assessment, charge or claim (a) whose amount,
applicability or validity is being contested in good faith by
appropriate proceedings or (b) for which NxStage has set
apart and maintains an adequate reserve.
Delivery of SEC and Other Reports to the
Trustee. NxStage will ensure delivery to the
trustee within 15 calendar days after it files annual and
quarterly reports, information, documents and other reports with
the SEC, copies of such reports and information, documents and
other reports which NxStage is required to file with the SEC
pursuant to Section 13 or 15(d) of the Exchange Act. If
NxStage at any time is no longer subject to the reporting
requirements of Section 13 or 15(d) of the Exchange Act, it
will continue to provide the trustee with reports containing
substantially the same information as NxStage would have been
required to file with the SEC if NxStage had continued to have
been subject to such reporting requirements. In such event,
NxStage will provide the trustee with such reports at the times
at which NxStage would have been required to provide the reports
if it had continued to have been subject to such reporting
requirements.
11
Additional Covenants. Any additional material
covenants of NxStage contained in an Indenture for a series of
debt securities offered by means of this prospectus, or any
deletions from or modifications of the covenants described
above, will be described in the prospectus supplement relating
to such series.
Consolidation,
Merger and Sale of Assets
Each Indenture provides that NxStage shall not consolidate with
or merge with or into, or convey, transfer or lease all or
substantially all of its properties and assets (as an entirety
or substantially as an entirety in one transaction or a series
of related transactions) to, another person, unless (1) the
resulting, surviving or transferee person (if not NxStage) is a
person organized and existing under the laws of the United
States of America, any state thereof or the District of
Columbia, and such entity (if not NxStage ) expressly assumes by
supplemental indenture, executed and delivered to the trustee in
form reasonably satisfactory to the trustee, all of the
obligations of NxStage under the applicable series of debt
securities and such Indenture and (2) immediately after
giving effect to such transaction, no default has occurred and
is continuing under such Indenture. Upon any such consolidation,
merger or transfer, the resulting, surviving or transferee
person shall succeed to, and shall be substituted for, and may
exercise every right and power of, NxStage under the applicable
Indenture.
Events of
Default, Notice and Waiver
Each Indenture provides that the following events are
Events of Default with respect to any series of debt
securities issued thereunder:
(1) default in any payment of interest on, or any
Additional Amounts payable in respect of, any debt security of
such series when due and payable, which default continues for a
specified period of days after the date when due and payable;
(2) default in the payment of the principal amount of (or
premium, if any, on) any debt security of such series when due
and payable at its stated maturity, upon required repurchase,
upon declaration or otherwise;
(3) failure by NxStage to comply with its obligations under
Consolidation, Merger and Sale of Assets;
(4) failure by NxStage for a specified period of days after
written notice from the trustee or the holders of a specified
amount in principal amount of such series of debt securities
then outstanding has been received by NxStage to comply with any
of its other agreements contained in the applicable
Indenture; and
(5) certain events of bankruptcy, insolvency, or
reorganization relating to NxStage or any Significant Subsidiary
of NxStage or any guarantor of any debt security of such series.
The term Significant Subsidiary means each
significant subsidiary of NxStage as defined in
Regulation S-X
promulgated under the Securities Act.
The prospectus supplement relating to a particular series of
debt securities may contain information relating to deletions
from, modifications of or additions to this list of events of
default.
If an Event of Default under either Indenture with respect to
debt securities of any series offered by means of this
prospectus at the time outstanding, other than an Event of
Default specified in clause (5) above, occurs and is
continuing, then in every such case the trustee or the holders
of not less than a specified amount in principal amount of the
outstanding debt securities of that series may declare the
principal amount (or, if the debt securities of that series are
original issue discount securities or indexed securities, such
portion of the principal amount as may be specified in the terms
thereof) of all of the outstanding debt securities of that
series to be due and payable immediately by written notice
thereof to NxStage (and to the applicable trustee if given by
the holders), and upon any such declaration such principal or
specified portion thereof shall become immediately due and
payable. If an Event of Default specified in clause (5)
above occurs, all unpaid principal of and accrued interest on
the outstanding debt securities of that series (or such lesser
amount as may be
12
provided for in the debt securities of such series) shall ipso
facto become and be immediately due and payable without any
declaration or other act on the party of the trustee or any
holder of any debt security of that series.
At any time after a declaration of acceleration with respect to
debt securities of the applicable series has been made, but
before a judgment or decree for payment of the money due has
been obtained by the applicable trustee, the holders of not less
than a majority in principal amount of outstanding debt
securities of such series may rescind and annul such declaration
and its consequences if (1) NxStage shall have paid or
deposited with the applicable trustee all required payments of
the principal of (and premium, if any) and interest, and any
Additional Amounts, on the debt securities of such series, plus
certain fees, expenses, disbursements and advances of the
trustee and (2) all Events of Default, other than the
non-payment of principal (or premium, if any) or interest on
debt securities of such series, have been cured or waived as
provided in the applicable Indenture. Each Indenture also
provides that the holders of not less than a majority in
principal amount of the outstanding debt securities of any
series may waive any past default with respect to such series
and its consequences, except a default (a) in the payment
of the principal of (or premium, if any) or interest or any
Additional Amounts on any debt security of such series,
(b) in the conversion or exchange of the debt securities in
accordance with their terms or (c) in respect of a covenant
or provision contained in the applicable Indenture that may not
be modified or amended without the consent of the holders of all
outstanding debt securities affected thereby.
Each trustee is required to give notice to the holders of debt
securities within 90 days after a default under the
applicable Indenture, except that the trustee may withhold
notice to the holders of any series of debt securities of any
default with respect to such series (except a default in the
payment of the principal of (or premium, if any) or interest or
any Additional Amounts on any debt security of such series or in
the payment of any sinking fund installment in respect of any
debt security of such series) if specified responsible officers
of the trustee consider in good faith such withholding to be in
the interest of such holders.
Each Indenture provides that no holders of debt securities of
any series offered by means of this prospectus may institute any
proceedings, judicial or otherwise, with respect to the
applicable Indenture or for any remedy thereunder, except in the
case of failure of the trustee thereunder, for a specified
period of days, to act after it has received a written request
to institute proceedings in respect of an Event of Default from
the holders of not less than a specified amount in principal
amount of the outstanding debt securities of such series (and no
direction inconsistent with such written request has been given
to the trustee by holders of a majority in principal amount of
the outstanding debt securities of that series), as well as an
offer of indemnity reasonably satisfactory to it. This
provision, however, will not prevent any holder of such debt
securities from instituting suit for the enforcement of payment
of the principal of (and premium, if any) and interest on, and
any Additional Amounts payable with respect to, such debt
securities at the respective due dates thereof or for the
enforcement of any conversion right in such debt securities.
Subject to provisions in each Indenture relating to its duties
in case of default, each trustee is under no obligation to
exercise any of its rights or powers under the applicable
Indenture at the request or direction of any holders of any
series of debt securities offered by means of this prospectus
then outstanding under such Indenture, unless such holders shall
have offered to the applicable trustee reasonable security or
indemnity satisfactory to the trustee. The holders of not less
than a majority in principal amount of the applicable
outstanding debt securities of any series shall have the right
to direct the time, method and place of conducting any
proceeding for any remedy available to the trustee, or of
exercising any trust or power conferred upon the trustee. The
trustee, however, may refuse to follow any direction which is in
conflict with any law or the applicable Indenture, which may
involve the trustee in personal liability or which may be unduly
prejudicial to the holders of debt securities of such series not
joining in such direction.
Within 120 days after the close of each fiscal year,
NxStage and each guarantor, if any, of any series of debt
securities offered by means of a prospectus supplement must
deliver to each trustee a certificate, signed by one of several
specified officers, as to such officers knowledge of its
compliance with all conditions and covenants of the applicable
Indenture and, in the event of any noncompliance, specifying
such noncompliance and the nature and status thereof.
13
Modification
of the Indentures
Subject to specified exceptions, each Indenture and any series
of debt securities outstanding under such Indenture may be
amended by a supplemental indenture with the consent of the
holders of at least a majority in principal amount of such
outstanding series of debt securities (including consents
obtained in connection with a purchase of, or tender offer or
exchange offer for, such series of debt securities) and, subject
to specified exceptions, any past default or compliance with any
provisions may be waived with the consent of the holders of at
least a majority in principal amount of such outstanding series
of debt securities. However, without the consent of each holder
of an outstanding debt security of such series affected thereby,
no amendment may, among other things:
|
|
|
|
|
reduce the amount of debt securities whose holders must consent
to an amendment or waiver;
|
|
|
|
reduce the rate of or extend the stated time for payment of
interest on any debt security;
|
|
|
|
reduce the principal amount of, or extend the stated maturity
of, any debt security;
|
|
|
|
make any change that adversely affects the conversion rights, if
any, of any debt security;
|
|
|
|
make any debt security payable in money other than that stated
in such debt security;
|
|
|
|
impair the right of any holder to receive payment of principal
(and premium, if any) and interest on, or any Additional Amounts
payable with respect to, such holders debt security on or
after the due dates thereof or to institute suit for the
enforcement of any payment on or with respect to such
holders debt security; or
|
|
|
|
modify the foregoing amendment provisions or the provisions
relating to waivers of past defaults, except to increase the
percentage of the principal amount of the debt securities whose
holders are required to consent to an amendment or waiver, or to
provide that certain other provisions of the applicable
Indenture may not be modified or waived without the consent of
the holder of each outstanding debt security affected thereby.
|
The holders of not less than a majority in principal amount of
any series of debt securities outstanding under either Indenture
have the right to waive compliance by NxStage with certain
covenants in the applicable Indenture with respect to that
series of debt securities.
Modifications and amendments of each Indenture may be made by
NxStage and the applicable trustee without the consent of any
holder of debt securities issued thereunder to:
|
|
|
|
|
cure any ambiguity, omission, defect or inconsistency contained
in the Indenture;
|
|
|
|
provide for the assumption by a successor corporation,
partnership, trust or limited liability company of the
obligations of NxStage under the Indenture;
|
|
|
|
provide for uncertificated debt securities in addition to or in
place of certificated debt securities (provided that the
uncertificated debt securities are issued in registered form for
purposes of Section 163(f) of the Internal Revenue Code, or
in a manner such that the uncertificated debt securities are
described in Section 163(f)(2)(B) of the Internal Revenue
Code);
|
|
|
|
add guarantees with respect to the debt securities;
|
|
|
|
secure the debt securities;
|
|
|
|
add to the covenants of NxStage for the benefit of the holders
of the debt securities, or to surrender any right or power
conferred upon NxStage;
|
|
|
|
comply with any requirement of the SEC to effect the
qualification of the Indenture under the Trust Indenture
Act; or
|
|
|
|
make any change that does not materially and adversely affect
the rights of the holders of the debt securities.
|
14
The consent of the holders is not necessary under the Indenture
to approve the particular form of any proposed amendment. It is
sufficient if such consent approves the substance of the
proposed amendment.
Each Indenture provides that in determining whether the holders
of the requisite principal amount of outstanding debt securities
of a series have given any request, demand, authorization,
direction, notice, consent or waiver thereunder or whether a
quorum is present at a meeting of holders of debt securities,
(1) the principal amount of an original issue discount
security that will be deemed to be outstanding will be the
amount of the principal thereof that would be (or shall have
been declared to be) due and payable as of the date of such
determination upon declaration of acceleration of the maturity
thereof, (2) the principal amount of a debt security
denominated in a foreign currency or currencies that will be
deemed outstanding will be the U.S. dollar equivalent,
determined on the issue date for such debt security, of the
principal amount (or, in the case of an original issue discount
security, the U.S. dollar equivalent on the issue date of
such debt security of the amount determined as provided in
clause (1) above), (3) the principal amount of an
indexed security that will be deemed outstanding will be the
principal face amount of such indexed security on the issue
date, unless otherwise provided with respect to such indexed
security pursuant to the applicable Indenture, and (4) debt
securities owned by NxStage or any other obligor upon the debt
securities or any affiliate of NxStage or of such other obligor
will be disregarded.
Each Indenture contains provisions for convening meetings of the
holders of debt securities of a series. A meeting may be called
by the trustee, by NxStage, pursuant to a resolution adopted by
its board of directors, or by the holders of not less than 10%
in principal amount of the outstanding debt securities of such
series, in any such case upon satisfaction of any conditions and
upon notice given as provided in the applicable Indenture.
Except for any consent that must be given by the holder of each
debt security affected by certain modifications and amendments
of the applicable Indenture, any resolution presented at a
meeting or adjourned meeting duly reconvened at which a quorum
is present may be adopted by the affirmative vote of the holders
of a majority in principal amount of the outstanding debt
securities of that series. Notwithstanding the foregoing, except
as referred to above, any resolution with respect to any
request, demand, authorization, direction, notice, consent,
waiver or other action that may be made, given or taken by the
holders of a specified percentage, which is less than a
majority, in principal amount of the outstanding debt securities
of a series may be adopted at a meeting or adjourned meeting
duly reconvened at which a quorum is present by the affirmative
vote of the holders of such specified percentage in principal
amount of the outstanding debt securities of that series. Any
resolution passed or decision taken at any meeting of holders of
debt securities of any series duly held in accordance with the
Indenture will be binding on all holders of debt securities of
that series. The quorum at any meeting called to adopt a
resolution, and at any reconvened meeting, will be persons
holding or representing a majority in principal amount of the
outstanding debt securities of a series, except that if any
action is to be taken at such meeting with respect to a consent
or waiver which may be given by the holders of not less than a
specified percentage in principal amount of the outstanding debt
securities of a series, the persons holding or representing such
specified percentage in principal amount of the outstanding debt
securities of such series will constitute a quorum.
Notwithstanding the provisions described above, if any action is
to be taken at a meeting of holders of debt securities of any
series with respect to any request, demand, authorization,
direction, notice, consent, waiver or other action that the
applicable Indenture expressly provides may be made, given or
taken by the holders of a specified percentage in principal
amount of all outstanding debt securities affected thereby, or
of the holders of such series and one or more additional series,
(1) there shall be no minimum quorum requirement for such
meeting and (2) the holders of the principal amount of the
outstanding debt securities of such series that vote in favor of
such request, demand, authorization, direction, notice, consent,
waiver or other action shall be taken into account in
determining whether such request, demand, authorization,
direction, notice, consent, waiver or other action has been
made, given or taken under the applicable Indenture.
Discharge,
Defeasance and Covenant Defeasance
NxStage may discharge certain obligations to holders of any
series of debt securities that have not already been delivered
to the trustee for cancellation and that either have become due
and payable or will become due and payable at their stated
maturity within one year (or scheduled for redemption within one
year) by
15
irrevocably depositing with the applicable trustee, in trust,
funds in such currency or currencies in which such debt
securities are payable in an amount sufficient to pay the entire
indebtedness on such debt securities in respect of the principal
(and premium, if any) and interest and Additional Amounts
payable to the date of such deposit (if such debt securities
have become due and payable) or to the stated maturity or date
of redemption, as the case may be.
Each Indenture provides that, if the provisions of the relevant
Article of such Indenture are made applicable to the debt
securities of (or within) any series pursuant to such Indenture,
NxStage may elect either (1) to effect a
defeasance, in which case it will be discharged from
any and all obligations with respect to such debt securities
(except for the obligation to pay Additional Amounts, if any,
and the obligations to register the transfer or exchange of such
debt securities, to replace temporary or mutilated, destroyed,
lost or stolen debt securities, to maintain an office or agency
in respect of such debt securities and to hold moneys for
payment in trust), or (2) to effect a covenant
defeasance, in which case it will be released from its
obligations with respect to the covenants described under
Certain Covenants or, if provided
pursuant to such Indenture, its obligations with respect to any
other covenant, and any omission to comply with such obligations
will not constitute a default or an Event of Default with
respect to such debt securities. Such defeasance or covenant
defeasance shall be effected upon the irrevocable deposit by
NxStage with the applicable trustee, in trust, of an amount, in
such currency or currencies in which such debt securities are
payable at their stated maturity, or Government Obligations (as
described below), or both, applicable to such debt securities
which through the scheduled payment of principal and interest in
accordance with their terms will provide money in an amount
sufficient to pay the principal of (and premium, if any) and
interest on such debt securities, and any mandatory sinking fund
or analogous payments thereon, on the scheduled due dates
therefor.
Such a trust may be established only if, among other things,
NxStage has delivered to the applicable trustee an opinion of
counsel (as specified in the applicable Indenture) to the effect
that the holders of such debt securities will not recognize
income, gain or loss for U.S. federal income tax purposes
as a result of such defeasance or covenant defeasance and will
be subject to U.S. federal income tax on the same amounts,
in the same manner and at the same times as would have been the
case if such defeasance or covenant defeasance had not occurred.
Each Indenture defines Government Obligations to
mean securities which are (1) direct obligations of the
United States of America or any government or governments which
issued the foreign currency or currencies in which the debt
securities of a particular series are payable, for the payment
of which its full faith and credit is pledged, or
(2) obligations of a person controlled or supervised by and
acting as an agency or instrumentality of the United States of
America or any such other government, the payment of which is
unconditionally guaranteed as a full faith and credit obligation
by the United States of America or such other government, which,
in either case, are not callable or redeemable at the option of
the issuer thereof. Government Obligations will also include a
depository receipt issued by a bank or trust company as
custodian with respect to any such Government Obligation or a
specific payment of interest on or principal of any such
Government Obligation held by such custodian for the account of
the holder of a depository receipt, except that (other than as
required by law) such custodian is not authorized to make any
deduction from the amount payable to the holder of such
depository receipt from any amount received by the custodian in
respect of the Government Obligation or the specific payment of
interest on or principal of the Government Obligation evidenced
by such depository receipt.
Unless otherwise provided in the applicable supplemental
indenture relating to any series of debt securities, if after
NxStage has deposited funds or Government Obligations to effect
defeasance or covenant defeasance with respect to debt
securities of any series, (1) the holder of a debt security
of such series is entitled to, and does, elect pursuant to the
applicable Indenture or the terms of such debt security to
receive payment in a currency other than that in which such
deposit has been made in respect of such debt security, or
(2) a Conversion Event (as described below) occurs in
respect of the currency in which such deposit has been made, the
indebtedness represented by such debt security and any coupons
appertaining thereto shall be deemed to have been, and will be,
fully discharged and satisfied through the payment of the
principal of (and premium, if any) and interest, if any, on such
debt security as they become due out of the proceeds yielded by
16
converting the amount or other property so deposited in respect
of such debt security into the currency in which such debt
security becomes payable as a result of such election or
Conversion Event based on the applicable market exchange rate.
Each Indenture defines Conversion Event to mean the
cessation of use of (a) a foreign currency other than the
Euro both by the government of the country which issued such
currency and for the settlement of transactions by a central
bank or other public institutions of or within the international
banking community, (b) the Euro both within the European
Monetary System and for the settlement of transactions by public
institutions of or within the European Community or (c) any
currency for the purposes for which it was established. Unless
otherwise provided in the applicable prospectus supplement, all
payments of principal of (and premium, if any) and interest on
any debt security that is payable in a foreign currency that
ceases to be used by its government of issuance shall be made in
U.S. dollars. If NxStage effects a covenant defeasance with
respect to any debt securities and such debt securities are
declared due and payable because of the occurrence of an Event
of Default, the amount in such currency in which such debt
securities are payable, and Government Obligations on deposit
with the applicable trustee, will be sufficient to pay amounts
due on such debt securities at the time of their stated maturity
but may not be sufficient to pay amounts due on such debt
securities at the time of the acceleration resulting from such
Event of Default. NxStage, however, would remain liable to make
payment of such amounts due at the time of acceleration.
The applicable prospectus supplement may further describe the
provisions, if any, permitting such defeasance or covenant
defeasance, including any modifications to the provisions
described above, with respect to the debt securities of or
within a particular series.
Senior
Debt Securities
Payment of the principal of and premium, if any, and interest on
debt securities we issue under the Senior Debt Securities
Indenture will rank equally with all of our unsecured and
unsubordinated debt.
Subordination
of Subordinated Debt Securities
To the extent provided in the Subordinated Debt Securities
Indenture and any supplemental indenture, and as described in
the prospectus supplement describing the applicable series of
subordinated debt securities, the payment of the principal of
and premium, if any, and interest on any subordinated debt
securities, including amounts payable on any redemption or
repurchase, will be subordinated in right of payment and junior
to senior indebtedness, which is defined below. If there is a
distribution to creditors of NxStage in a liquidation or
dissolution of NxStage, or in a bankruptcy, reorganization,
insolvency, receivership or similar proceeding relating to
NxStage, the holders of senior indebtedness will first be
entitled to receive payment in full of all amounts due on the
senior indebtedness (or provision shall be made for such payment
in cash) before any payments may be made on the subordinated
debt securities. Because of this subordination, general
creditors of NxStage may recover more, ratably, than holders of
subordinated debt securities in the event of a distribution of
assets upon insolvency.
The supplemental indenture will set forth the terms and
conditions under which, if any, we will not be permitted to pay
principal, premium, if any, or interest on the related
subordinated debt securities upon the occurrence of an event of
default or other circumstances arising under or with respect to
senior indebtedness.
The Indentures will place no limitation on the amount of senior
indebtedness that we may incur. We expect to incur from time to
time additional indebtedness constituting senior indebtedness,
which may include indebtedness that is senior to the
subordinated debt securities but subordinate to our other
obligations.
The Subordinated Debt Securities Indenture defines senior
indebtedness as the principal of, and premium, if any,
interest, including any interest accruing after the commencement
of any bankruptcy or similar proceeding, whether or not a claim
for post-petition interest is allowed as a claim in the
proceeding, and rent payable on or in connection with, and all
fees, costs, expenses and other amounts accrued or due on or in
connection with, Indebtedness of NxStage, whether secured or
unsecured, absolute or contingent, due or to become due,
outstanding on the date of the indenture or thereafter created,
incurred, assumed, guaranteed or in
17
effect guaranteed by NxStage, including all deferrals, renewals,
extensions or refundings of, or amendments, modifications or
supplements to, the foregoing. Senior indebtedness does not
include:
|
|
|
|
|
indebtedness that expressly provides that such indebtedness
(1) shall not be senior in right of payment to the
subordinated debt securities, (2) shall be equal or junior
in right of payment to the subordinated debt securities, or
(3) shall be junior in right of payment to any of
NxStages other indebtedness;
|
|
|
|
any indebtedness of NxStage to any of its majority-owned
subsidiaries, other than indebtedness to NxStages
majority-owned subsidiaries arising by reason of guarantees by
NxStage of indebtedness of such subsidiary to a person that is
not NxStages subsidiary; and
|
|
|
|
indebtedness for trade payables or the deferred purchase price
of assets or services incurred in the ordinary course of
business.
|
DESCRIPTION
OF PREFERRED STOCK
General
Our restated certificate of incorporation provides that we may
issue up to 5,000,000 shares of preferred stock, par value
$0.001 per share. As of September 30, 2010, there were no
series of preferred stock authorized or shares of preferred
stock outstanding.
The following description of the preferred stock sets forth
general terms and provisions of the preferred stock to which any
prospectus supplement may relate. The statements below
describing the preferred stock are in all respects subject to
and qualified in their entirety by reference to the applicable
provisions of our restated certificate of incorporation and
amended and restated bylaws and any applicable certificates of
designation to our restated certificate of incorporation
designating terms of a series of preferred stock. The issuance
of preferred stock could adversely affect the voting power,
dividend rights and other rights of holders of common stock.
Although our board of directors does not have this intention at
the present time, it could establish a series of preferred
stock, that could, depending on the terms of the series, delay,
defer or prevent a transaction or a change in control of our
company that might involve a premium price for the common stock
or otherwise be in the best interest of the holders thereof.
Terms
The board of directors is authorized, subject to limitations
prescribed by law and the Companys restated certificate of
incorporation, to provide for the issuance of shares of
preferred stock in series, by filing a certificate pursuant to
applicable law of the State of Delaware, to establish the number
of shares to be included in each such series, and to fix the
designation, relative rights, preferences, qualifications and
limitations of the shares of each such series. The number of
authorized shares of preferred stock may be increased or
decreased (but not below the number of shares thereof
outstanding) by the affirmative vote of the holders of a
majority of the Companys stock entitled to vote, without a
vote of the holders of the preferred stock, or any series
thereof, unless a vote of any such holders is required pursuant
to the certificate or certificates establishing any series of
preferred stock.
Reference is made to the prospectus supplement relating to the
series of preferred stock offered thereby for the specific terms
thereof, including:
|
|
|
|
|
the title and stated value of the preferred stock;
|
|
|
|
the number of shares of the preferred stock, the liquidation
preference per share of the preferred stock and the offering
price of the preferred stock;
|
|
|
|
the dividend rate(s), period(s)
and/or
payment day(s) or method(s) of calculation thereof applicable to
the preferred stock;
|
|
|
|
the date from which dividends on the preferred stock shall
accumulate, if applicable;
|
18
|
|
|
|
|
the procedures for any auction and remarketing, if any, for the
preferred stock;
|
|
|
|
the provision for a sinking fund, if any, for the preferred
stock;
|
|
|
|
the provision for redemption, if applicable, of the preferred
stock;
|
|
|
|
any listing of the preferred stock on any securities exchange;
|
|
|
|
the terms and conditions, if applicable, upon which the
preferred stock may or will be convertible into our common
stock, including the conversion price or manner of calculation
thereof;
|
|
|
|
the relative ranking and preferences of the preferred stock as
to dividend rights and rights upon liquidation, dissolution or
winding up of our affairs;
|
|
|
|
a discussion of U.S. federal income tax considerations
applicable to the preferred stock; and
|
|
|
|
any other specific material terms, preferences, rights,
limitations or restrictions of the preferred stock.
|
Voting
Rights
The DGCL provides that the holders of preferred stock will have
the right to vote separately as a class on any proposal
involving fundamental changes in the rights of holders of that
preferred stock. This right is in addition to any voting rights
that may be provided for in the applicable certificate of
designation.
Stockholder
Liability
Delaware law provides that no stockholder, including holders of
preferred stock, shall be personally liable for our acts and
obligations and that our funds and property shall be the only
recourse for these acts or obligations.
Transfer
Agent and Registrar
The transfer agent and registrar for the preferred stock will be
set forth in the applicable prospectus supplement.
DESCRIPTION
OF WARRANTS
As of the date of this prospectus, there are warrants
outstanding to purchase up to in the aggregate
7,133,329 shares of our common stock.
We may issue warrants for the purchase of common stock, debt
securities, preferred stock or any combination of the foregoing
securities. Warrants may be issued independently or together
with our securities offered by any prospectus supplement. Series
of warrants may be issued under a separate warrant agreement.
The applicable prospectus supplement will describe the terms of
the warrants offered, including but not limited to the following:
|
|
|
|
|
the number of warrants offered;
|
|
|
|
the price or prices at which the warrants will be issued;
|
|
|
|
the currency or currencies in which the prices of the warrants
may be payable;
|
|
|
|
securities for which the warrants are exercisable;
|
|
|
|
whether the warrants will be issued with any other securities
and, if so, the amount and terms of these securities;
|
|
|
|
the amount of securities purchasable upon exercise of each
warrant and the price at which and the currency or currencies in
which the securities may be purchased upon such exercise, and
the events or conditions under which the amount of securities
may be subject to adjustment;
|
19
|
|
|
|
|
the date on which the right to exercise such warrants shall
commence and the date on which such right shall expire;
|
|
|
|
the circumstances, if any, which will cause the warrants to be
deemed to be automatically exercised;
|
|
|
|
the minimum or maximum amount of such warrants, if any, that may
be exercised at any one time;
|
|
|
|
any material risk factors relating to such warrants; and
|
|
|
|
any other material terms of such warrants.
|
Prior to the exercise of any warrants, holders of such warrants
will not have any rights of holders of the securities
purchasable upon such exercise, including the right to receive
payments of dividends, or the right to vote such underlying
securities.
Prospective purchasers of warrants should be aware that special
United States federal income tax, accounting and other
considerations may be applicable to instruments such as
warrants. The applicable prospectus supplement will describe
such considerations, to the extent they are material, as they
apply generally to purchasers of such warrants.
SELLING
SECURITYHOLDERS
Selling securityholders are persons or entities that, directly
or indirectly, have acquired or will from time to time acquire
from us, securities in various private transactions. Such
selling securityholders may be parties to registration rights
agreements with us, or we otherwise may have agreed or will
agree to register their securities for resale. The initial
purchasers of our securities, as well as their transferees,
pledges, donees or successors, all of whom we refer to as
selling securityholders, may from time to time offer
and sell the securities pursuant to this prospectus and any
applicable prospectus supplement.
The applicable prospectus supplement will set forth the name of
each of the selling securityholders and the number of shares of
our common stock beneficially owned by such selling
securityholders that are covered by such prospectus supplement.
LEGAL
MATTERS
The legal validity of the securities offered by this prospectus
will be passed upon for us by Hogan Lovells US LLP.
EXPERTS
The consolidated financial statements of NxStage Medical, Inc.
appearing in NxStage Medical Inc.s Annual Report
(Form 10-K)
for the year ended December 31, 2009, and the effectiveness
of NxStage Medical Inc.s internal control over financial
reporting as of December 31, 2009 have been audited by
Ernst & Young LLP, independent registered public
accounting firm, as set forth in their reports thereon, included
therein, and incorporated herein by reference. Such consolidated
financial statements are incorporated herein by reference in
reliance upon such reports given on the authority of such firm
as experts in accounting and auditing.
20
3,200,000 Shares
NxStage Medical, Inc.
Common Stock
PROSPECTUS SUPPLEMENT
Canaccord Genuity
November 17, 2010